Research Appraisals
Evidence-based critical appraisals of the latest medical research, systematically evaluated using Oxford CEBM methodology.
Showing 90 appraisals
Human vaccines & immunotherapeutics
Artificial intelligence in immune checkpoint inhibitor research: A bibliometric analysis of the landscape
This bibliometric analysis examines the transformative role of artificial intelligence (AI) in immune checkpoint inhibitor (ICI) research. Using VOSviewer, CiteSpace, and Bibliometrix, we analyzed 1,938 publications from the Web of Science Core Collection (2015-2026), revealing a dramatic rise in AI-related ICI studies, led by China and the USA. Key findings demonstrate AI's integration in predicting treatment response, optimizing dosing strategies, and managing immune-related adverse events. Through keyword co-occurrence and citation analyses, we identify critical AI applications including digital pathology and tumor microenvironment characterization. This comprehensive overview provides valuable insights into research trends and emerging frontiers for AI-driven innovations in cancer immunotherapy.
30 July 2026
Read appraisal →Journal of robotic surgery
From robot assistance to surgical intelligence: global research trends and emerging frontiers of artificial intelligence-enhanced robotic surgery in urology.
To systematically characterize global publication trends, collaboration patterns, intellectual foundations, research hotspots, and emerging frontiers in artificial intelligence (AI)-enhanced robotic and robot-assisted surgery in urology. Publications were retrieved from the Web of Science Core Collection (WoSCC) using a topic search strategy that included three keyword groups: robot-assisted surgery, urologic diseases or procedures, and AI-related technologies. English-language articles and reviews were included. Meeting abstracts, conference proceedings, editorials, letters, non-English publications, studies unrelated to urologic robotic surgery, and studies without substantive AI or intelligent algorithmic content were excluded. RStudio was used for descriptive statistics and annual publication trend visualization. VOSviewer was used for auxiliary bibliometric network construction and visualization. CiteSpace was used to construct collaboration networks, co-citation networks, keyword co-occurrence maps, cluster maps, timeline and time-zone maps, and citation burst maps. A total of 401 records were initially retrieved, and 253 publications were finally included after screening by document type, language, and topical relevance. These comprised 199 articles (78.66%) and 54 reviews (21.34%). Publications in this field began in 2004 and increased rapidly after 2018, reaching a peak of 53 publications in 2025. Because 2026 was an incomplete retrieval year, only 23 publications were recorded. Italy, the United States, the Netherlands, China, and Japan were the leading contributing countries. The University of Turin, Azienda Ospedaliero-Universitaria San Luigi Gonzaga, IRCCS Fondazione del Piemonte per l'Oncologia, the Netherlands Cancer Institute, and Leiden University Medical Center were the most productive institutions. Keyword clustering showed that the major research hotspots included renal cell carcinoma, augmented reality, image-guided surgery, indocyanine green, machine learning, registration, deep learning, and bladder cancer. AI-enhanced robotic surgery in urology has evolved from early research on registration, navigation, and image-guided surgery toward a surgical intelligence stage characterized by augmented reality, three-dimensional reconstruction, machine learning-based prediction, deep learning-based segmentation, surgical video understanding, and skill assessment. Future studies should prioritize multicenter standardized datasets, sharing of intraoperative video and robotic platform data, model interpretability, prospective validation, and integration into real-world clinical workflows.
27 July 2026
Read appraisal →Journal of robotic surgery
Robot-assisted versus open kidney transplantation: an umbrella review of systematic reviews and meta-analyses
Robot-assisted kidney transplantation (RAKT) has emerged as a minimally invasive alternative to open kidney transplantation (OKT). However, the comparative benefits and limitations of both approaches remain unclear. To compare the outcomes of RAKT and OKT through an umbrella review of published systematic reviews and meta-analyses. This umbrella review was written following PRISMA guidelines. Only meta-analysis and systematic review were included. Many outcomes were studied such as warm (WIT) and cold ischemia times (CIT), rewarming time, total ischemia time, blood loss, blood transfusion, delayed graft function, surgical site infections (SSI), hospital stay, graft rejection, graft failure, all-cause mortality, operation time, incision length, hospital readmission, vascular and ureteral anastomosis time, and other complications. We assessed methodological quality via the AMSTAR-2 tool. Consistency and strength of evidence were also evaluated. 6 studies were included: four meta-analyses and two systematic reviews. Studies were of low to moderate quality. Robotic kidney transplant surgery yields better outcomes in terms of blood loss (MDs ranging from - 16 to - 55 mL across studies), post-operative pain, incision length, SSI and ureteral leak. On the other hand, CIT, rewarming time, total ischemia time, operative time and ileus rate were favored in open surgery. Same rejection rates, graft failure, mortality and hospital readmission rate were found between both techniques. RAKT appears to improve several perioperative outcomes while maintaining comparable graft and patient survival outcomes to OKT. However, the available evidence remains limited by the low-to-moderate quality of existing reviews, highlighting the need for high-quality prospective studies.
27 July 2026
Read appraisal →Journal of robotic surgery
Reliability and readability of AI chatbot responses to patient questions about robot-assisted radical cystectomy
Robot-assisted radical cystectomy (RARC) is a complex procedure that requires patients to understand surgical indications, urinary diversion, perioperative treatment, complications, recovery, and long-term functional outcomes. Although artificial intelligence (AI) chatbots are increasingly used to obtain medical information, their suitability for RARC patient education remains unclear. We conducted a cross-sectional comparative evaluation of four contemporary AI chatbots: ChatGPT-5, DeepSeek-V4, Claude Sonnet 4.6, and Gemini 3.5 Pro. A set of 20 core patient-education questions on RARC was developed by three senior urologic experts. Chatbot responses were assessed using DISCERN, the Ensuring Quality Information for Patients tool, the Global Quality Scale, and JAMA benchmark criteria. Readability was evaluated using the Automated Readability Index, Coleman-Liau Index, Flesch-Kincaid Grade Level, Flesch Reading Ease, Gunning Fog Index, and SMOG. Reliability scores differed significantly across models for DISCERN, EQIP, and GQS, while JAMA benchmark criteria were summarized descriptively as transparency signals. DeepSeek-V4 achieved the highest mean scores for DISCERN, EQIP, and GQS, while ChatGPT-5 and DeepSeek-V4 showed the strongest JAMA benchmark performance. Gemini 3.5 Pro generally had the lowest reliability and transparency scores. Readability also varied across models. DeepSeek-V4 produced the most readable responses overall, whereas Gemini 3.5 Pro generated the most complex text. However, all models exceeded the recommended sixth-grade reading level, and FRES scores remained below the recommended threshold. Contemporary AI chatbots generated responses with variable presentation quality, transparency, and readability for common RARC patient-education questions. Because factual accuracy was not directly assessed, these tools should not be interpreted as validated sources of clinical guidance and should not replace individualized counseling by urologists.
23 July 2026
Read appraisal →Journal of robotic surgery
Transfer of technical skills from virtual reality robotic simulation to non-virtual surgical performance: a systematic review and meta-analysis
Virtual Reality Robotic Surgery Simulators (VR-RSS) are widely used, but their educational value depends on whether skills acquired in virtual reality (VR) training transfer to non-virtual performance. This review evaluated whether VR training improves transferable robotic surgical skills. We searched PubMed, Scopus, Web of Science, and Cochrane from inception to March 3, 2026, for randomized trials evaluating VR robotic simulator training with transfer to non-virtual settings. Screening was performed in Rayyan. Data were extracted systematically, risk of bias was assessed with RoB 2, and random-effects meta-analyses using Hedges' g were conducted in R. Eight trials were included in the review, and seven were included in meta-analysis. Sample sizes ranged from 12 to 35 participants. Although the pooled standardized mean difference (SMD) for global technical skill scores favored the VR training group, it did not reach statistical significance (g = 0.77, 95% CI -0.64-2.18; p = 0.205). Task completion time was also shorter in the VR training group, but this difference was not statistically significant (g = 0.47, 95% CI -0.35-1.29; p = 0.164). This review suggests a potential benefit of VR-based robotic simulation for transferring trained skills to non-VR environments. Future studies should include larger sample sizes and longitudinal assessments using validated metrics to better characterize these trends.
21 July 2026
Read appraisal →Journal of robotic surgery
Transperitoneal versus retroperitoneal single-port robot-assisted partial nephrectomy: systematic review and meta-analysis of perioperative and functional outcomes
To systematically compare the safety and efficacy of the transperitoneal (TP) and retroperitoneal (RP) approaches in single-port robot-assisted partial nephrectomy (SP-RAPN). PubMed, Web of Science, and Embase were searched for comparative studies published before October 2025. The primary evaluated outcomes were grouped as Perioperative Outcomes (operative time, blood loss, ischemia time, positive surgical margin, postoperative eGFR, and hospital stay) and Surgical Safety (complication rate). Study inclusion and exclusion standards followed the PICOS guidelines. Four comparative studies with 384 patients (188 TP and 196 RP) were analyzed. Compared with the RP group, the TP group had higher intraoperative blood loss (WMD = 27.95 mL, 95% CI = 4.90-51.02, p = 0.018), longer hospital stay (WMD = 0.56 days, 95% CI = 0.34-0.78, p < 0.001), and higher absolute postoperative eGFR (WMD = 6.87, 95% CI = 2.65-11.10, p = 0.001). Operative time did not differ significantly in the main analysis (p = 0.356); an exploratory sensitivity analysis suggested a possible small difference (≈ 12 min) that requires confirmation. Warm ischemia time, positive surgical margin rate, and complication rate showed no significant differences between the two groups. Sensitivity analysis confirms the robustness of these findings, with overall low heterogeneity. Both transperitoneal and retroperitoneal SP RAPN are safe and feasible based on this limited evidence. Preliminary findings suggest the RP approach may offer advantages in blood loss, hospital stay, and renal preservation, but these results are hypothesis generating. Importantly, tumor location strongly influenced approach selection, and observed differences may be attributable to tumor location rather than the approach itself; causal inference is not possible from this observational data. Validation in larger, prospective, and preferably randomized studies is required.
21 July 2026
Read appraisal →Journal of robotic surgery
Safety and feasibility of robotic telesurgery in urological procedures: a systematic review and meta-analysis of clinical data
Robotic telesurgery has emerged as a potential solution to expand access to specialized surgical care; however, clinical evidence remains fragmented across procedures and robotic platforms. We conducted this meta-analysis to assess the feasibility and safety of robotic telesurgery across urological procedures. An electronic search was conducted on PubMed, Scopus, Web of Science (WoS) and the Cochrane Library from inception through April 2026 according to PRISMA guidelines. Clinical studies reporting robotic telesurgery in urology were included regardless of study design. The primary outcome of interest was procedural success, defined as completion without conversion to a local surgeon or an alternative surgical approach. Secondary outcomes included complication rates and round-trip latency (RTL). Nineteen studies involving 164 patients were included. The pooled procedural success rate was 0.92 (95% CI: 0.86-0.96). No conversions to open or laparoscopic surgery were reported across the included studies. The pooled complication rate was 0.12 (95% CI: 0.07-0.20), with events occurring in a limited number of studies. RTL data were available from 14 studies, with a pooled mean latency of 123.30 milliseconds (ms) (95% CI: 81.76-164.83) demonstrating substantial heterogeneity (I² = 99.99%). Robotic telesurgery in urology demonstrates excellent technical feasibility and a favorable short-term safety profile in carefully selected cases. However, variability in network performance and procedure-specific requirements remain important considerations. Further prospective studies with standardized reporting and long-term outcome assessment are needed before widespread clinical adoption can be recommended.
21 July 2026
Read appraisal →Journal of robotic surgery
Technical advancements in robot-assisted radical prostatectomy: systematic review and bibliometric analysis
Robot-assisted radical prostatectomy has transformed the surgical management of localized prostate cancer, yet its research landscape remains incompletely mapped. We conducted a systematic review and bibliometric analysis of 578 articles and conference papers from Scopus and Web of Science (2005-2026), following PRISMA guidelines, and analyzed publication trends, geographic and institutional distribution, author networks, journal output, keyword co-occurrence, and thematic evolution. The results reveal exponential growth in research, with an inflection around 2015-2016 and accelerated momentum after 2020, reflecting the widespread adoption and maturation of robotic programs. The United States leads in publication volume, followed by Italy and the rapidly growing contribution of China, while The University of Turin (Italy) emerges as the most productive institution due to its pioneering Retzius-sparing approach; the Journal of Robotic Surgery remains the leading publication venue. Thematic analysis demonstrates a progression from early feasibility studies to the standardization of nerve-sparing and continence-preserving techniques, advancing toward single-port surgery, augmented reality navigation, and AI-assisted intraoperative decision-making. Emerging technologies such as augmented reality, the NeuroSAFE protocol, and deep learning models for outcome prediction are particularly transformative, and geographic disparities are highlighted as critical priorities for future research.
21 July 2026
Read appraisal →Journal of robotic surgery
Mapping the evolution of deep learning and computer vision in robotic surgery: a bibliometric analysis of surgical video intelligence, instrument perception, and clinical translation.
Deep learning and computer vision are increasingly embedded in robotic surgery, yet the development and translational direction of this research domain remain incompletely characterized. We conducted a bibliometric and visualization analysis of publications retrieved from the Web of Science Core Collection using Bibliometrix/Biblioshiny, VOSviewer, and CiteSpace. A total of 1,186 documents published between 2010 and 2026 across 356 sources were included. Scientific output increased rapidly, with an annual growth rate of 16.09% and a peak of 216 publications in 2025. The field involved 5,296 authors, and international collaboration accounted for 30.69% of publications. IEEE Robotics and Automation Letters was the most productive and locally influential source. China and the United States were the leading contributors, with China showing the most rapid recent expansion and the United States retaining the highest citation impact. Citation-burst and keyword analyses identified U-Net, residual learning, transformer architectures, and foundation-model-enabled segmentation as major methodological drivers. The conceptual structure evolved from image guidance, registration, and navigation toward surgical video intelligence, instrument perception, workflow understanding, autonomous assistance, and clinical translation. Instrument perception emerged as a central link between algorithmic development and operative application. Future progress will require diverse multi-institutional datasets, external and prospective validation, integrated scene understanding, and rigorous evaluation of intelligent assistance within real robotic surgical workflows.
21 July 2026
Read appraisal →Journal of robotic surgery
Technology-enhanced training in basic robotic surgical skills: a systematic review
Robotic surgery has seen substantial growth, however training access remains limited by resources and time-intensive credentialling pathways. Technology enhanced learning may address these barriers whilst improving training efficiency and assessment objectivity. We aimed to systematically evaluate technology-enhanced approaches to basic robotic surgical skills training. This systematic review followed PRISMA guidelines with prospective registration (OSF: V93MZ). MEDLINE (via OVID), Embase, and the Cochrane Library (CENTRAL and CDSR) were searched on 23 May 2025 without date restrictions. Technologies included virtual reality, augmented reality, sensor-based systems, video review, and performance feedback. Risk of bias was assessed using the RoB-2 and ROBINS-I tools, and certainty of evidence using GRADE. Narrative synthesis was utilised given methodological heterogeneity, with reported outcomes mapped to the Kirkpatrick model of training evaluation. Seventeen studies involving 484 participants were included (10 randomised trials, 7 prospective cohort studies; 16 single-centre). Technologies comprised virtual reality (7), sensor-based systems (5), performance feedback (3), video review (1), and augmented reality (1); no eligible artificial intelligence studies were identified. Virtual reality, utilised within bespoke robotic simulators, demonstrated accelerated learning curves, although some systems required more repetitions than traditional robotic simulator-based training. The single augmented reality study improved instrument velocity. Sensor-based force measurement devices improved force application and ergonomics. Video review improved accuracy but temporarily increased completion time. Multimodal feedback systems outperformed conventional feedback. Evidence was concentrated at Kirkpatrick level 2 (learning); one study reported only level 1 (reaction) data, with no studies reporting level 3 or 4 outcomes. Risk of bias was low in randomised studies and low-moderate in non-randomised studies. Technology-enhanced basic robotic skills training has evidence supporting improved performance outcomes, accelerated learning curves, and enhanced objective assessment capabilities. Gaps persist for basic skills training in augmented reality, artificial intelligence, and docking and setup. Standardised competency assessment frameworks are required to evaluate these rapidly progressing tools.
21 July 2026
Read appraisal →European journal of clinical pharmacology
Clomiphene citrate versus testosterone replacement therapy in male hypogonadism: a systematic review of literature and meta-analysis
INTRODUCTION: Male hypogonadism, including age-related and functional forms, is characterized by insufficient testosterone production often associated with obesity and metabolic comorbidities. Testosterone replacement therapy (TRT) increases serum testosterone but suppresses spermatogenesis and may cause adverse effects. Selective estrogen receptor modulators (SERMs), such as clomiphene citrate, have emerged as an alternative approach to restore endogenous testosterone while preserving fertility. This study aimed to compare the efficacy of clomiphene citrate versus testosterone replacement therapy (TRT) in increasing serum testosterone levels in men with hypogonadism. METHODS: We conducted a systematic review of the literature in PubMed, Embase, Scopus, The Cochrane Library, and Google Scholar to identify studies comparing clomiphene citrate and testosterone replacement therapy (TRT) in men with male hypogonadism'. The primary outcome was the change in serum testosterone levels before and after treatment. Secondary outcomes included variations in other hormonal parameters, and clinical symptom improvement assessed through standardized instruments. RESULTS: A total of 11 studies with 1512 patients were included (764 on clomiphene citrate; 748 on testosterone replacement therapy, TRT). For serum testosterone, the overall pooled effect showed no significant difference between clomiphene and TRT (MD = 6.64 ng/dL; 95% CI -35.35 to 48.63; I² = 80.6%). Subgroup analyses indicated injectable testosterone achieved higher levels than clomiphene (1 study, 62 patients; MD = -290.50; 95% CI -518.78 to -62.22), whereas gel-based TRT showed no difference (8 studies, 1012 patients; MD = 24.29; 95% CI -18.91 to 67.48; I² = 76.1%). For sexual function, three studies (199 patients; 85 on clomiphene; 114 on TRT) assessing post-treatment libido (ADAM 1-5) showed lower libido scores with clomiphene than TRT (MD = - 0.54; 95% CI - 0.87 to - 0.21; P = 0.009; I² = 18.8%). CONCLUSIONS: No statistically significant difference in serum testosterone levels was observed between clomiphene citrate and testosterone gel, although the evidence is limited by high heterogeneity and some concerns to high risk of bias. TRT was associated with greater improvements in libido. These findings should be interpreted as preliminary, and large-scale randomized trials incorporating clinical and fertility endpoints are needed.
13 July 2026
Read appraisal →BMJ open
Development and acceptability of gist-based decision aids for prostate and breast cancer screening: a two-phase qualitative interview study in an online setting.
BACKGROUND: Traditional approaches to designing decision aids have focused on providing completeness of information and quantitative detail. An alternative approach based on psychological research emphasises understanding the essence or 'gist' of the decision. Few gist-based decision aids exist. The objective of this study was to develop novel gist-based decision aids for prostate and breast cancer screening and evaluate their acceptability. METHODS: Men aged 40-60 years and women aged 40-49 years eligible for prostate or breast cancer screening were recruited from ResearchMatch (National Institutes of Health) and a public hospital located in New York City. Three rounds of semistructured interviews were performed to determine self-reported comprehensibility and acceptability, with iterative modifications after each phase, including: Phase 1: initial feedback; Phase 2, Round 1: evaluating our modifications; and Phase 2, Round 2: confirming final content. RESULTS: A total of 80 participants were involved in the two-phase qualitative interview process; Phase 1 and Phase 2 included 32 and 48 participants, respectively. Racial distribution was 50% white, 30% black and 10% Asian; 9% of participants were Hispanic or Latino. Most participants were highly educated. Interview themes established content validity of the final decision aids. In a quantitative analysis of the final decision aids using a questionnaire with fixed response options, acceptability was high, with two-thirds finding the length and amount of information of the decision aid to be optimal. The majority found the decision aid visually appealing, easy to read and easy to get through, and indicated that it held their interest and did not require much mental effort to read. One-quarter said the tool made them feel somewhat nervous, and three-quarters not at all. Most participants could understand and relate to the images, graphs and patient stories in the decision aid. After Phase 2, 45 of the 48 participants (94%) said they would find the decision aid helpful when making a decision. CONCLUSION: This study describes the iterative development and pilot testing of a novel gist-based decision aid for cancer screening, demonstrating high acceptability. Our findings provide a foundation for randomised trials comparing gist-based and traditional tools.
10 July 2026
Read appraisal →Journal of medical Internet research
Magnetic Resonance Imaging-Based Artificial Intelligence in Predicting Prostate Cancer Biochemical Recurrence: Systematic Review and Meta-Analysis
BACKGROUND: Artificial intelligence (AI) has emerged as a promising tool for prostate cancer (PCa) risk stratification and outcome prediction. However, current studies often lack multicenter external validation, have limited sample sizes, present significant intermodel variability, and face overfitting concerns. OBJECTIVE: This study aimed to comprehensively evaluate the diagnostic performance of magnetic resonance imaging (MRI)-based AI models in predicting biochemical recurrence (BCR) of PCa. METHODS: Systematic searches were conducted in the PubMed, Embase, Web of Science, and Cochrane Library databases up to January 13, 2026. Studies were included that involved participants diagnosed with PCa, used MRI-based AI for predicting BCR, and had clearly defined reference standards. The quality of the included studies was assessed using the PROBAST+AI tool. A bivariate random effects model was used to pool sensitivity, specificity, and area under the curve (AUC) statistics. RESULTS: A total of 28 studies were included, with 2623 patients in internal validation and 1134 patients in external validation. Diagnostic contingency tables were reconstructed from published performance metrics for most studies, while others were extracted from receiver operating characteristic curves due to the lack of direct reporting. In the internal validation set, pooled sensitivity was 0.80 (95% CI 0.73-0.86; prediction interval [PI] 0.48-0.99), specificity was 0.83 (95% CI 0.77-0.89; PI 0.49-1.00), and AUC was 0.86 (95% CI 0.83-0.89; PI 0.74-0.99). In the external validation set, pooled sensitivity was 0.82 (95% CI 0.72-0.91; PI 0.54-0.99), specificity was 0.83 (95% CI 0.71-0.92; PI 0.49-1.00), and AUC was 0.84 (95% CI 0.79-0.90; PI 0.70-0.98). No statistically significant differences were observed between internal and external validation in sensitivity (P=.73), specificity (P>.99), AUC (P=.53), or diagnostic odds ratio (P=.98). Medical Net and Extreme Gradient Boosting achieved the highest sensitivity and AUC, whereas multiple kernel learning and support vector machine had the highest specificity. Subgroup and meta-regression analyses suggested that AI method, model type, timing of MRI acquisition, and treatment modality may contribute to heterogeneity. CONCLUSIONS: This meta-analysis innovatively realizes the quantitative direct comparison of MRI-based AI model performance between internal and external validation cohorts for PCa BCR prediction. It comprehensively evaluates AI performance across diverse PCa treatment modalities and integrates machine learning and deep learning approaches. For the field, it identifies key sources of performance heterogeneity (eg, MRI acquisition timing and treatment modality) and quantifies the sensitivity-specificity trade-off in integrated radiomic-clinical models, advancing the systematic understanding of MRI-based AI for BCR prediction. In real-world practice, it provides actionable guidance to prioritize pretreatment MRI for AI model development and clinical BCR assessment and underscores the urgent need for standardized imaging protocols and prospective multicenter studies, laying a foundation for the safe clinical translation of these AI tools as adjunctive decision support instruments.
8 July 2026
Read appraisal →Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine
Integrating Artificial Intelligence into Prostate MR Imaging: Technical Foundations, Clinical Applications, and Workflow Implications
Prostate MRI has become a cornerstone of contemporary prostate cancer diagnosis, enabling improved detection of clinically significant disease while reducing unnecessary biopsies and overtreatment. However, prostate MRI remains technically demanding, time-consuming, and subject to inter-reader variability, particularly as healthcare systems move toward abbreviated protocols such as non-contrast MRI (biparametric MRI). In this context, artificial intelligence (AI) has emerged as a promising tool to enhance image quality, diagnostic consistency, and workflow efficiency across the prostate MRI pathway. This non-systematic narrative review provides a comprehensive overview of the technical foundations, clinical applications, and workflow implications of AI integration into prostate MRI. It summarizes key concepts in machine learning and deep learning relevant to prostate imaging and reviews current evidence supporting AI-based solutions for image quality assessment and reconstruction, automated prostate segmentation, lesion detection, and risk stratification. Particular attention is given to human-AI collaboration models, the role of AI in supporting equivocal lesions, and the integration of imaging with clinical variables for personalized risk estimation. In addition, it discusses the impact of AI on reporting efficiency, training, and standardization, as well as the current landscape of commercially available AI tools. Despite encouraging results from large multicenter studies, important challenges remain, including heterogeneity in study design, limited prospective validation, generalizability across institutions, and ethical and regulatory considerations. Overall, AI should be regarded as a complementary decision-support technology rather than a replacement for radiologists. Thoughtful implementation, robust validation, and appropriate user training are essential to ensure that AI meaningfully enhances the quality, efficiency, and reliability of prostate MRI-based care.
2 July 2026
Read appraisal →Urolithiasis
A validated custom pipeline for three-dimensional kidney stone renderings to create an open access repository
Three-dimensional (3D) rendering of urologic pathology plays an important role in simulation-based education, surgical training, and computer vision research; however, a standardized, open-access repository of high-fidelity kidney stone models stratified by chemical composition is lacking. We developed and validated a reproducible photogrammetry-based pipeline to generate realistic 3D kidney stone renderings. Chemically characterized human stones composed of calcium oxalate monohydrate (COM) (n = 11), uric acid (UA) (n = 5), cystine (n = 4), magnesium ammonium phosphate hexahydrate/carbonate apatite (MAPH/CA) (n = 2), and calcium hydrogen phosphate dihydrate (CHPD) (n = 3) were photographed using a custom-built rotating stage and dual fixed 4 K cameras. Rendered models were sent to 25 endourologists using a 5-point Likert-scale survey assessing geometric and surface texture fidelity. Successful 3D renderings were obtained for 8/11 COM stones, 5/5 UA stones, 2/2 MAPH/CA fragments, and 3/3 CHPD fragments, while all cystine stones failed to render. Across stone types, mean fidelity scores were highest for UA and COM stones (mean 3.8-3.9), intermediate for calcium phosphate stones (mean 3.6-3.8), and lowest for struvite stones (mean 3.0-3.3). Geometry scores were higher than texture scores overall, though this difference was not significant. Significant differences in geometric fidelity were observed across stone compositions (χ² = 9.30, p = 0.026). Inter-rater reliability was poor for individual evaluators (ICC = 0.10) but moderate for aggregated mean ratings (ICC = 0.67). This validated workflow enables the creation of generally realistic, open-access 3D kidney stone models (github.com/uro-glidar/3d-rendering-diverse-stones) for simulation, education, and future machine learning applications in endourology.
21 June 2026
Read appraisal →Journal of robotic surgery
Robot-assisted peritoneal flap vaginoplasty in gender-affirming genital reconstruction: a systematic review and single-arm meta-analysis
Robot-assisted peritoneal flap vaginoplasty has emerged as an evolving reconstructive option in gender-affirming genital surgery. This systematic review and single-arm meta-analysis aimed to synthesize the available evidence regarding its perioperative, functional canal, and postoperative safety outcomes. This study was conducted according to PRISMA guidelines and prospectively registered in PROSPERO. PubMed, Cochrane Library, Embase, and Web of Science were searched from database inception to May 2026. Eligible studies included transfeminine or gender-diverse individuals undergoing robot-assisted peritoneal flap-based vaginoplasty with extractable clinical outcomes. Continuous outcomes were synthesized as weighted mean estimates with 95% confidence intervals (CIs), and overall postoperative complications were pooled using Stata version 18.0. Heterogeneity was assessed using the I² statistic, and leave-one-out sensitivity analyses were performed. Ten studies involving 974 patients were included. The pooled mean operative time was 305.37 min (95% CI 244.62, 366.12), and the pooled length of hospital stay was 5.80 days (95% CI 4.72, 6.87). At the last available follow-up, pooled neovaginal depth was 13.41 cm (95% CI 12.86, 13.96), and pooled neovaginal width was 3.61 cm (95% CI 3.55, 3.67). The pooled overall postoperative complication rate was approximately 30.1%. Sensitivity analyses suggested that the pooled estimates were not driven by any single study. Robot-assisted peritoneal flap vaginoplasty appears feasible and may achieve neovaginal dimensions broadly comparable to those reported for other full-depth vaginoplasty approaches. However, predominantly retrospective single-arm evidence precludes conclusions regarding superiority and highlights the need for standardized prospective studies with longer follow-up and patient-reported outcomes.
20 June 2026
Read appraisal →European radiology experimental
Digital twin technologies in prostate cancer as a frontier for precision medicine
Prostate cancer (PCa) is the most frequently diagnosed malignancy among men and presents major clinical and socioeconomic challenges worldwide. Despite advances in early detection, imaging, and therapy, managing PCa remains complex due to disease heterogeneity, risks of overdiagnosis, and overtreatment. Digital twin (DT) technologies might represent an emerging conceptual framework aimed at supporting dynamic, patient-specific virtual modeling for personalized clinical decision-making. By integrating multimodal clinical, imaging, molecular, and physiological data, DTs can simulate disease progression, predict treatment responses, and support proactive, adaptive care. This perspective explores the conceptual framework for DT ecosystems in PCa, highlighting potential clinical impacts, infrastructural requirements, and barriers to implementation. Harnessing DTs could impact PCa management into a truly predictive, personalized, and participatory approach, improving outcomes and optimizing healthcare resource utilization globally. RELEVANCE STATEMENT: DT technologies may enable personalized, predictive PCa management by integrating multimodal patient data to guide diagnosis, treatment selection, and monitoring, with the potential to improve outcomes, reduce overtreatment, and optimize healthcare resource utilization KEY POINTS: DTs create virtual patient models to personalize PCa care. They integrate imaging, clinical, and molecular data into one system. This approach may reduce overdiagnosis and unnecessary treatments.
20 June 2026
Read appraisal →Journal of global health
Plasma proteomic signatures predict incident benign prostatic hyperplasia: a prospective cohort study of 20 996 men
BACKGROUND: Benign prostatic hyperplasia (BPH) is a prevalent disease in elderly men. However, the plasma proteomic signatures for incident BPH are absent, hindering early prediction and risk stratification. We aimed to identify plasma proteins associated with incident BPH and the implicated biological pathways. METHODS: This prospective cohort was constructed based on the UK Biobank, enrolling 20 996 BPH-free males at baseline. We used the Olink Explore platform to determine the abundances of 2920 plasma proteins. We used Cox regression models to evaluate associations and the Extreme Gradient Boosting model to perform feature selection and predictive modelling. We performed pathway enrichment and Mendelian randomisation analyses to elucidate the molecular pathways involved and assess causality. RESULTS: During the median follow-up period of 13.38 years, 2405 incident BPH cases were recorded. Cox regression identified 92 plasma proteins significantly associated with BPH risk (false discovery rate <0.05). Extreme Gradient Boosting model prioritised a three-protein signature: TSPAN1 (hazard ratio (HR) = 1.24) and KLK3 (HR = 1.34) as risk factors, and EDA2R (HR = 0.83) as a protective factor. This three-protein panel achieved an AUC of 0.71 (95% confidence interval = 0.69-0.73) for predicting BPH onset. Enrichment analysis revealed the associated proteins were mainly involved in immune-inflammatory pathways and stromal remodelling. As revealed by Mendelian randomisation, TSPAN1 and KLK3 were causally associated with incident BPH. CONCLUSIONS: We identified a three-protein panel (TSPAN1, KLK3, EDA2R) which can predict incident BPH. The findings highlight potential targets for non-invasive risk assessment and therapy.
15 June 2026
Read appraisal →Journal of robotic surgery
The need for a dedicated surgical consent framework for robotic telesurgery: a global call to action
Robotic telesurgery has progressed from experimental demonstrations to real-world clinical implementation across multiple continents. Landmark interconnected procedures, including intercontinental robotic prostatectomies, humanitarian implementations in underserved regions, and expansion of teleproctoring/tele-mentoring networks, showcase a rapidly maturing field. Despite this proliferation, no standardized, procedure-specific surgical consent for telesurgery exists in the medical literature. Current consent processes for robotic surgery, telemedicine, and surgical research fail to address critical elements unique to telesurgery, including latency thresholds, technical redundancies, network architecture, cybersecurity risks, remote surgeon responsibilities, and contingency planning. Our article aims to define the essential elements that should compose a dedicated telesurgery-specific informed consent and to highlight why current consent frameworks are insufficient for this rapidly expanding global practice. This expert-opinion paper synthesizes high-impact literature on consent ethics, digital surgery, telehealth governance, and robotic surgery; evaluates current consents used in pioneering telesurgery programs across North America, South America, Africa, Europe, and Asia; and incorporates multidisciplinary insights from surgery, anesthesiology, biomedical engineering, cybersecurity, telecommunications, ethics, and global health. We identify major gaps in contemporary consent frameworks, including (1) inadequate disclosure of connectivity-related risks; (2) insufficient explanation of data transmission, cybersecurity, and encryption; (3) absence of latency thresholds and safety-based interruption criteria; (4) lack of transparency regarding remote surgeon responsibility and handover protocols; and (5) limited patient education regarding contingency conversion and chain-of-care accountability. We thus propose a 9-component International Telesurgery Consent Framework, providing standardized language and structure for global implementation. The rapid expansion of telesurgery demands an equally rapid evolution in patient-centered informed consent. A dedicated telesurgery consent should become the ethical, medicolegal, and operational standard for any remote robotic clinical procedure. This paper serves as the basis for an international consensus effort involving global leaders in robotic surgery, telehealth, AI-enabled surgery, and digital health regulation.
14 June 2026
Read appraisal →World journal of urology
The urologic impact of long-term finasteride 1-mg use for androgenic alopecia: a matched-cohort database analysis
INTRODUCTION AND OBJECTIVES: Since its approval in 1997, finasteride-1 mg (F1) can be taken daily to treat androgenic alopecia (AA) by reducing serum dihydrotestosterone (DHT). When finasteride is prescribed at the 5 mg dosage, the DHT reduction is known to affect sexual function, reduce serum prostate-specific antigen (PSA) levels and treat benign prostatic hyperplasia (BPH). However, there is no literature on the urologic function of men using long-term F1. Thus, we aimed to address this knowledge gap by analyzing a database for the impact of F1 on urologic function. METHODS: Using the Truveta database, we identified men aged 18 + diagnosed with AA per International Classification of Diseases (ICD) coding, with at least 90 days of F1 use and ≥ 5 years of follow-up. Exclusions included patients with a history of anti-depressant usage, prior diagnosis (Dx) or treatment (Tx) of erectile dysfunction (ED), BPH, or prostate cancer (PC). A control cohort with AA but no F1 use was matched based on age, race, ethnicity, and marital status. We compared Dx rates, Tx rates, and time to Dx or Tx using Chi-square and Kruskal-Wallis Rank sum tests. Survival analysis was performed with restricted mean survival time. RESULTS: We identified 3470 patients with long-term F1 use and 3470 matched patients with AA but no F1 use. The average age for the F1 group was 40.59 and 39.75 for the control. Average F1 use duration was 2011.5 days. Median follow-up was 2554.7 days for the F1 group, and 3129.5 days for the control. The F1 group had higher phosphodiesterase type 5 inhibitor (PDE5i) prescription rate (13.6% vs. 10.5%, p < 0.001) and earlier prescription by 238.6 days (95% CI -304.3, -172.9, p < 0.0001). The control group had a higher -blocker prescription rate (4.4% vs. 2.9%, p = 0.001). There were no significant differences in ED diagnosis, BPH Dx rates or time-to BPH diagnosis or α-blocker prescription. The F1 group had lower elevated PSA Dx and PC Dx rates (2.9% vs. 4.4%, p < 0.001; 0.9% vs. 1.8%, p = 0.001). CONCLUSIONS: Though ED diagnosis did not differ significantly, patients on long-term F1 for AA were more likely to be prescribed PDE5i and sooner by approximately 230 days, compared to non-F1 users. F1 did not significantly affect BPH Dx or Tx rates. F1 use was associated with decreased PC and elevated PSA Dx rates. More research on urologic effects of chronic F1 use in AA patients is needed.
9 June 2026
Read appraisal →Radiation oncology (London, England)
HyperSightTM-CBCT based monitoring of sarcopenia during definitive radiotherapy of prostate cancer: a longitudinal feasibility study
BACKGROUND: Sarcopenia and treatment-related muscle loss are associated with increased toxicity and reduced resilience in cancer patients. HyperSight™ cone-beam CT (CBCT) provides improved soft-tissue contrast compared with conventional CBCT and may enable reliable longitudinal skeletal-muscle monitoring during image-guided radiotherapy (IGRT). This study evaluated the feasibility of HyperSight™ CBCT-based muscle assessment in prostate cancer patients and explored the clinical relevance of intratreatment muscle decline. METHODS: Eighty-eight patients with non-metastatic prostate cancer were treated on an Ethos® system with HyperSight™ CBCT. Patients received ultrahypofractionated (UHF) or normo-/moderately hypofractionated (NF/MHF) radiotherapy; 28% received androgen-deprivation therapy. Cross-sectional muscle area (CSA) and radiodensity (HU) were assessed on planning CT (PCT) and serial CBCTs (first, second, last fraction [FF, SF, LF]); HU values were z-standardized to subcutaneous fat (zHU). Agreement between PCT and CBCT was evaluated using concordance correlation coefficients (CCC), regression, and Bland-Altman analysis. Longitudinal changes were analyzed using mixed-effects models, and associations with acute genitourinary/gastrointestinal (GU/GI) toxicity (RTOG ≥ 2) using regression models. RESULTS: HyperSight™ CBCT showed excellent agreement with PCT for CSA (CCC = 0.981). The NF/MHF cohort showed a significant longitudinal CSA decline (FF-LF: -153.0 mm², p = 0.021), whereas no significant within-cohort change was observed in UHF. Muscle density (zHU) decreased significantly in both cohorts (NF/MHF: p < 0.001; UHF: p = 0.0017). Weight loss and age were independently associated with zHU change, while no independent predictors of CSA decline were identified. In the NF/MHF cohort, CSA loss > 5% was associated with acute GU toxicity in univariate analysis (OR 4.90, p = 0.033; Fisher's exact p = 0.014), but not after adjustment for age, weight loss, ECOG performance status, and ADT; no associations were found for GI toxicity or in the UHF cohort. CONCLUSIONS: HyperSight™ CBCT enables quantitative skeletal-muscle assessment during prostate radiotherapy and detects intratreatment reductions in muscle density, which may represent an early imaging marker of muscle decline. Muscle loss showed an exploratory association with acute GU toxicity in NF/MHF patients in univariate analysis, but not after adjustment. These findings support the feasibility of CBCT-based muscle monitoring and warrant further evaluation in larger cohorts. CLINICAL TRIAL NUMBER: Not applicable.
1 June 2026
Read appraisal →Journal of robotic surgery
Comparative efficacy and safety of open, laparoscopic, and robot-assisted radical cystectomy: a systematic review and network meta-analysis
The most appropriate surgical strategy for radical cystectomy in bladder cancer remains to be established. This study performed a network meta-analysis of randomized controlled trials to evaluate open, laparoscopic, and robot-assisted approaches. Outcomes were systematically classified into intraoperative metrics, postoperative recovery, perioperative safety, and oncological efficacy. A random effects model was employed, and treatment hierarchy was determined using the surface under the cumulative ranking curve. Eleven studies comprising 1270 patients met the inclusion criteria. Compared with open surgery, minimally invasive techniques were associated with reduced intraoperative blood loss and lower transfusion rates, although they required longer operative time. Among these, laparoscopic surgery was associated with a potentially greater likelihood of enhanced postoperative recovery and fewer complications, although these findings should be interpreted with caution given the sparse network and substantial heterogeneity in some outcomes. Robot-assisted procedures did not demonstrate consistent superiority over laparoscopy in perioperative measures. Oncological outcomes were similar across all modalities. Overall, minimally invasive approaches confer perioperative benefits and appear comparable to open surgery with respect to short-term surrogate oncological endpoints, although long-term outcomes remain to be determined.
31 May 2026
Read appraisal →World journal of urology
Assessing multiple chatGPT versions on novel content in the Taiwan urology board examination: accuracy, speed, and domain-specific performance
PURPOSE: Large language models demonstrate increasing utility in healthcare; however, their capacity to handle newly developed medical content beyond training data boundaries remains unclear. This study evaluated the performance of four ChatGPT models on 120 newly developed questions from the 2024 Taiwan Urology Board Examination, all created after the models' October 2023 training cutoff, thereby reducing the risk of prior model exposure. METHODS: Model performance was assessed using accuracy and processing time. Of 150 examination items, the first 120 newly developed questions constituted the primary analysis set; the remaining 30 previously used archival questions were excluded to reduce potential bias from prior exposure. The primary paired accuracy comparison evaluated o1-preview versus GPT-4o across all 120 questions. Additional analyses across 12 urological subspecialties and question-complexity strata were treated as exploratory. RESULTS: Across all 120 questions, o1-preview achieved 66.7% accuracy and significantly outperformed GPT-4o (55.8%; p = 0.012), although with longer processing time (19.20 vs. 14.94 s). Performance varied significantly across 12 urological subspecialties (p < 0.001). Unlike the other tested models, o1-preview showed slightly higher accuracy on high-complexity than on low-complexity questions (68.3% vs. 65.0%). On high-complexity surgical anatomy items, o1-preview achieved 80.0% accuracy, whereas GPT-4o and GPT-4o mini both scored 0.0% (p = 0.024). CONCLUSION: On this newly developed post-cutoff, text-based urology board question set, o1-preview achieved higher overall accuracy than GPT-4o, particularly on high-complexity surgical anatomy items, at the cost of longer response times. These findings suggest that reasoning-oriented models may offer advantages for selected specialty-level assessment tasks, although generalizability to other languages, modalities, and clinical settings requires further validation.
30 May 2026
Read appraisal →JMIR medical informatics
Multimodal Prediction of Renal Tumor Malignancy From Radiology Reports and Structured Electronic Health Records: Retrospective Cohort Study
BACKGROUND: Accurate preoperative prediction of renal tumor malignancy is critical for guiding decisions and reducing overtreatment, as a substantial proportion of renal masses prove benign. Although radiology assessments and structured electronic health record (EHR) data are routinely used, many tumor-specific descriptors remain embedded in free-text radiology reports and are underused due to extraction challenges. OBJECTIVE: This study aimed to develop and evaluate a multimodal pipeline that integrates structured EHR variables with natural language processing features from computed tomography (CT) radiology reports, including large language model (LLM)-extracted abnormality characteristics and transformer-based report embeddings, to improve malignancy prediction. METHODS: We conducted a retrospective cohort study using University of Florida Health Integrated Data Repository Observational Medical Outcomes Partnership-mapped EHR data from December 2011 to August 2024. Adults with renal tumors were included if they had longitudinal diagnostic documentation consistent with a renal mass and at least 1 preoperative renal CT report; final benign or malignant status served as the outcome. Structured features included demographics, comorbidities, medications, vital signs, and laboratory measurements. From the recent preindex CT report, an on-premises LLM isolated kidney-specific findings and extracted abnormality characteristics. Four locally deployed LLMs were evaluated against manual annotations of 500 reports. Kidney-specific text was encoded using pretrained biomedical transformer models, including radiology Bidirectional Encoder Representations from Transformers (BERT) variants. We evaluated unimodal baselines and multimodal early, middle, and late fusion strategies. Model development used 5-fold cross-validation within the 80% training partition; each fold-specific model was evaluated on the same independent 20% held-out test set, with performance reported as mean and SD across the 5 held-out test evaluations. The primary metric was area under the receiver operating characteristic curve (AUC). RESULTS: The final cohort included 967 patients (n=712, 73.6% malignant). In extraction evaluation, Qwen2.5-32B achieved 88.3% overall accuracy with a 100% extraction success rate and was selected for downstream feature generation. Among unimodal models, the structured clinical variable model achieved an AUC of 0.758 (SD 0.012), kidney-specific text with radiology BERT achieved an AUC of 0.746 (SD 0.058), and abnormality characteristics alone achieved an AUC of 0.716 (SD 0.015). Multimodal fusion models achieved higher descriptive performance than unimodal models. Early fusion achieved the highest AUC (mean 0.813, SD 0.008), and F1-score (mean 0.809, SD 0.030), while late fusion achieved an AUC of 0.805 (SD 0.016). Ablation and interpretability analyses suggested complementary predictive information from structured clinical variables and kidney-specific text embeddings. CONCLUSIONS: Integrating unstructured radiology report text with structured EHR variables achieved higher mean predictive performance than unimodal approaches in descriptive comparisons. Multimodal fusion, particularly early fusion incorporating radiology BERT-derived kidney-specific text embeddings, achieved the strongest discrimination, suggesting potential value of natural language processing-enabled multimodal EHR pipelines for informing preoperative risk stratification.
28 May 2026
Read appraisal →JMIR medical informatics
Usability and Usefulness of Machine Learning-Based Clinical Decision Support Software in Primary Care: Survey of Users in a Prospective Observational Study
BACKGROUND: The successful implementation of decision support systems promises to enhance high-quality care. However, the successful implementation of a clinical decision support system (CDSS) depends on user acceptance and adoption. A machine learning (ML)-based CDSS to assist primary care professionals treating urinary tract infections (UTIs) was implemented, and usability and usefulness were assessed through a questionnaire. OBJECTIVE: This study aimed to assess the system's usability by examining users' experiences with the software. A secondary goal was to assess users' attitudes toward evidence-based practice and innovation in health care. METHODS: In collaboration with the Netherlands Institute for Health Services Research (NIVEL) and Leiden University Medical Center (LUMC), Pacmed Ltd developed the CDSS. The cohort was mostly recruited at the care group level; practices within participating care groups were required to participate. Health insurers partly funded the research. Practitioners participated in the implementation study for 4 months. A survey based on the Unified Theory of Acceptance and Use of Technology (UTAUT) was sent to 263 general practitioners and assistants shortly after the implementation period. Furthermore, usage data were analyzed. RESULTS: Of the 34 participating practices that used the software, 30 (88%) submitted at least one survey response, with a mean of 2.23 responses per practice (SD 1.43). The CDSS was used throughout the pilot period, and 31 practices continued using the tool, with 9% dropping out during the first 8 weeks. Sixty-seven percent of respondents trusted the tool's output, and 73% found it understandable how the algorithm came to predictions. Sixty-five percent of respondents indicated that the information provided was useful in addition to the available guidelines, and 52% agreed that it supported their decision-making. However, many respondents were uncertain whether the tool improved patient care (46%) or patient outcomes (66%). Forty-eight percent of respondents found the software easy to integrate into their clinical workflow. CONCLUSIONS: The CDSS was perceived as trustworthy and easy to use. However, users were unable to determine whether the CDSS improved patient outcomes. In addition, the CDSS development could have benefited from including assistants as well as general practitioners more in the design phase of the software. Because assistants play an important role in UTI care, designing the software to better fit existing workflows may reduce the perceived time investment associated with using the tool. Finally, respondents reported strong motivation to contribute to further research in this field and indicated willingness to embrace change in health care delivery, which may also reflect selection bias in our sample.
28 May 2026
Read appraisal →BMC urology
Comparison of suction and standard ureteral access sheath versus sheathless flexible ureteroscopy in management of upper ureteral and renal calculi
PURPOSE: Comparative effectiveness of suction versus traditional ureteral access sheath (UAS) remains an area of ongoing research. We aim to compare the outcomes of retrograde intrarenal surgery (RIRS) with suction and standard UAS versus without UAS in the management of renal and upper ureteric stones, with a specific focus on operative efficiency, stone-free rates, and postoperative complications. METHODS: This study was conducted between October 2023 and January 2025, including 90 patients with renal stones ≤ 3 cm and upper ureteric stones ≤ 1.5 cm. Patients were divided into three groups by random Allocation Software (version 2): Group A1 (standard UAS, n = 30), Group A2 (suction UAS, n = 30), and Group B (no UAS, n = 30). Operative time, vision quality, stone clearance, complications, and hospital stay were assessed. RESULTS: Group A2 had the shortest mean operative time (70.1 ± 10.3 min) with significantly better vision compared to Group A1 (114.3 ± 27.0 min) and Group B (125.0 ± 28.01 min) (p < 0.001). Residual stone rates were lowest in Group A2 (3.3%) compared to Group A1 (10.0%) and Group B (26.7%) (p = 0.035). The need for a second procedure was significantly higher in Group B (26.7%) compared to Group A1 (10.0%) and absent in Group A2 (p = 0.002). Hospital stay was significantly shorter in Group A2 compared to Group A1 and Group B (p = 0.005). Fever incidence (Clavien Grade II) was significantly higher in Group B (23.3%) compared to Group A1 (16.7%) and absent in Group A2 (p = 0.005). CONCLUSION: Suction ureteral access sheaths in flexible ureteroscopic lithotripsy for renal stones ≤ 3 cm and upper ureteric stones ≤ 1.5 cm was associated with improved stone clearance, reduced operative time and hospital stay, provide better endoscopic vision, minimized infectious complications and need for second procedure, compared to standard UAS or no sheath. However, outcomes may be influenced by surgeon experience and familiarity with suction-assisted systems. Prospective multicenter studies with larger sample sizes and varying surgeon experience levels are recommended.
27 May 2026
Read appraisal →World journal of urology
Retrograde intrarenal surgery versus miniaturized percutaneous nephrolithotomy for renal calculi: a grade-assessed meta-analysis of randomized controlled trials with trial sequential analysis
BACKGROUND: The optimal management of medium-sized (1-3 cm) renal stones remains a clinical dilemma, with retrograde intrarenal surgery (RIRS) and miniaturized percutaneous nephrolithotomy (mPCNL) serving as competing minimally invasive options. To overcome the selection bias inherent in previous meta-analyses that included observational data, we aimed to compare the efficacy and safety of both techniques by exclusively analyzing randomized controlled trials (RCTs). METHODS: A systematic literature search of five databases was conducted up to February 2026. Only RCTs comparing RIRS and mPCNL were included. The primary outcomes were the single session stone-free rate (SFR) and overall complication rate. Secondary outcomes included stone clearance-related outcomes, operative performance outcomes, and recovery-related outcomes. Data were pooled using a random-effects model, and trial sequential analysis (TSA) was applied. RESULTS: Thirty RCTs encompassing 4173 patients were included. mPCNL demonstrated a significantly higher single-session SFR compared to RIRS (R.R: 0.92, 95% C.I: 0.88-0.96, p < 0.001). RIRS showed a trend toward a lower overall complication rate although the difference did not reach statistical significance (RR = 0.79, 95% CI: 0.63-1.01; p = 0.057), reduced blood transfusion requirements, smaller hemoglobin drops, and shorter hospitalization times. However, RIRS required significantly more postoperative auxiliary procedures. Operative times and high-grade Clavien-Dindo III-V complication rates were comparable between both techniques. TSA confirmed that the cumulative evidence for single-session SFR was sufficient and conclusive, whereas TSA findings for overall complication rate should be interpreted cautiously. CONCLUSIONS: mPCNL achieves significantly higher SFR than RIRS in the management of 1-3 cm renal calculi. However, RIRS was associated with lower bleeding-related morbidity and shorter hospitalization, although no statistically significant difference was observed in the overall complication rate. Therefore, the choice between RIRS and mPCNL should be individualized, balancing maximal SFR against procedural invasiveness according to patient characteristics and stone complexity.
25 May 2026
Read appraisal →World journal of urology
From conventional imaging software to artificial intelligence: tools for stone volume assessment in urolithiasis. Α review by the EAU and YAU sections of endourology.
INTRODUCTION: Accurate assessment of stone burden is fundamental in urolithiasis, as it directly influences treatment selection and prognostic evaluation. Although maximum stone diameter on non-contrast computed tomography remains the most widely used parameter, it does not adequately reflect the three-dimensional complexity of urinary calculi. This review aimed to summarize the evolution of stone burden assessment from conventional imaging-based methods to software-assisted volumetry and artificial intelligence (AI)-driven tools, with emphasis on their accuracy, reproducibility, and clinical utility. METHODS: A narrative review of the literature was performed using PubMed/MEDLINE, Scopus, and Google Scholar for English-language studies published up to March 2026. Original studies, validation studies, technical reports, reviews, and guideline-related papers addressing conventional CT-based measurement, software-assisted volumetry, AI-based stone segmentation, and the clinical significance of stone volume were included. Due to heterogeneity in study design and reported outcomes, the evidence was synthesized narratively. RESULTS: Maximum stone diameter remains simple and widely available, but it incompletely represents true stone burden, particularly in larger or irregular stones. Formula-based ellipsoid calculations are practical yet show limited accuracy in complex geometries. Semi-automated CT-based segmentation software provides more reliable volumetric assessment, with excellent agreement with reference standards and reduced interobserver variability. AI-based approaches have further improved efficiency by enabling rapid and highly accurate automated stone detection and volume calculation. Across the reviewed literature, stone volume was consistently shown to be more clinically informative than linear dimensions for predicting spontaneous passage, stone-free rates after shockwave lithotripsy and ureteroscopy, and future symptomatic events during surveillance. CONCLUSIONS: Stone volume offers a more accurate and clinically meaningful estimate of stone burden than maximum stone diameter alone. The transition from formula-based methods to software-assisted and AI-driven volumetry represents an important advance in urolithiasis imaging. Wider adoption will depend on standardized imaging protocols, improved software accessibility, and validation of volume-based thresholds for routine clinical practice.
25 May 2026
Read appraisal →Current urology reports
Association Between Ambient Temperature and Urolithiasis: A Systematic Review and Meta-analysis
PURPOSE OF REVIEW: The global incidence of urolithiasis has risen in recent decades. Emerging evidence suggests that higher ambient temperatures are linked to an increased risk of kidney-stone-related events, including acute renal colic, likely through physiological mechanisms such as increased urinary calcium excretion and greater supersaturation of calcium oxalate and calcium phosphate. This study aims to systematically review existing evidence on the relationship between ambient temperature and urolithiasis risk. RECENT FINDINGS: Of 892 records identified, 46 studies met the inclusion criteria for the systematic review, and 16 were included in the meta-analysis. Most studies reported a positive association between higher ambient temperatures and increased kidney stone-related events, with seasonal peaks occurring during summer months in the Northern Hemisphere and from December to March in Australia. Considerable heterogeneity was observed in exposure definitions, meteorological data sources, outcome ascertainment, and lag structures. Reported effect estimates ranged from RR 1.10 to 2.54. Meta-analysis showed that higher ambient temperature was associated with an increased risk of urolithiasis presentation (pooled RR 1.31, 95% CI 1.21-1.43; I²=86.7%). Subgroup analyses showed pooled RRs of 1.27 (95% CI 1.18-1.37) for stone colic, 1.33 (95% CI 1.06-1.67) for emergency visits, and 1.36 (95% CI 0.98-1.90) for hospitalizations. Associations were stronger at medium and long lag periods than at short lags. Most studies were rated as high risk of bias, primarily because of confounding and outcome measurement concerns. Sensitivity analyses supported the robustness of the findings. This systematic review highlights an association between higher ambient temperatures and increased presentations for kidney stone disease. Addressing environmental factors may be a valuable strategy for reducing nephrolithiasis incidence.
25 May 2026
Read appraisal →ACS sensors
Urine-Based Noninvasive Detection of Prostate Cancer Using Human Olfactory Receptor-Embedded Nanodiscs
The diagnosis of prostate cancer (PCa) is limited by the low specificity of prostate-specific antigen (PSA) testing, which contributes to overdiagnosis and patient exposure to unnecessary invasive prostate biopsies. Here, we report a urine-based diagnostic platform that combines a six-member human olfactory receptor-embedded nanodisc (OR-ND) sensor array with fluorescence sensing and machine learning to detect PCa-associated volatile organic compounds (VOCs). Six ORs were reconstituted into lipid nanodiscs and evaluated using urine samples from a strictly curated subcohort of 40 PCa patients and 33 healthy controls (n = 73) to establish baseline sensor responsiveness. Subsequently, to ensure diagnostic robustness, machine learning classifiers were developed and cross-validated using an expanded data set of 290 samples, achieving an accuracy of 0.890 and an AUC of 0.964. Analysis of the full receptor data set revealed distinct response patterns, and statistical screening with correlation filtering identified OR2W1, OR51E1, and OR51E2 as the most informative features. Using these selected receptors, a random forest classifier achieved an accuracy of 0.890 and an AUC of 0.964, demonstrating high sensitivity and specificity. OR response patterns showed a closer association with Gleason score than with serum PSA levels, indicating that urinary VOC signatures capture tumor-related metabolic information complementary to conventional biomarkers. These results demonstrate that an OR-ND sensor array coupled with machine learning enables accurate and noninvasive detection and classification of PCa from urine samples. Our study provides a modular framework extensible to other VOC-associated diseases.
23 May 2026
Read appraisal →Journal of robotic surgery
Intraoperative surgical needle loss in robotic-assisted and laparoscopic surgery: a systematic review and practical troubleshooting framework
Intraoperative loss of a surgical needle during minimally invasive surgery (MIS) is uncommon but clinically important. In robotic-assisted surgery (RAS), altered sensory conditions and evolving trocar designs may influence both needle-loss mechanisms and retrieval strategy. We systematically reviewed the literature and developed a practical troubleshooting framework. PubMed, Embase, CNKI, and Wanfang were searched from inception to January 2026 in accordance with PRISMA 2020. Studies reporting intraoperative needle loss during abdominal or pelvic MIS or RAS were included. Because of substantial heterogeneity, findings were synthesized narratively. Thirty-three studies were included, comprising 27 original studies and 6 narrative reviews. Quantitative outcome aggregation was restricted to clinical patient-level studies, yielding 37 extractable lost-needle events: 22 during RAS and 15 during conventional laparoscopy. Minimally invasive retrieval was successful in 35/37 cases, whereas incision extension or open conversion was required in 2/37. Recurrent practical risk scenarios included trocar-pathway entrapment, including the hypothesized "Trocar Trap," and possible risk amplification related to absent haptic feedback in RAS. Evidence supporting adjunctive localization tools, including fluoroscopy and magnetic assistance, remained limited and largely non-comparative. Needle loss in contemporary MIS and RAS should be regarded as a workflow-sensitive patient safety event supported mainly by low-level evidence. The most relevant contemporary implications concern robotic workflow, port-pathway inspection, disciplined handoff, and selective use of adjunctive retrieval tools within a stepwise troubleshooting framework. Registration: PROSPERO (CRD420261294460).
22 May 2026
Read appraisal →Journal of robotic surgery
Emerging robotic platforms in partial nephrectomy: a comparative systematic review and network meta-analysis
Robotic-assisted partial nephrectomy (RAPN) is the preferred minimally invasive nephron-sparing technique, with outcomes comparable to open and laparoscopic surgery. While most evidence derives from the da Vinci system, newer robotic platforms such as Hugo, Hinotori, KangDuo and MP1000 are emerging. This systematic review and network meta-analysis evaluated perioperative outcomes across available RAPN platforms. A systematic search of PubMed, Cochrane Library, CINAHL, and Scopus identified studies reporting RAPN outcomes across available robotic platforms. Eligible studies included randomized and observational cohorts. Risk of bias was assessed with ROBINS-I. Outcomes included in the analysis operative time (OT), estimated blood loss (EBL), and length of hospital stay (LOS). A frequentist NMA using the "netmeta" R package generated standardized mean differences (SMD) with 95% CIs, and P-scores ranked platform performance. The review was registered on PROSPERO (ID: CRD420251032233). This review was conducted in accordance with PRISMA guidelines. Thirteen studies (n = 2,450) were included. Under fixed-effects model, da Vinci SP (SMD - 0.63, 95% CI - 0.87 to - 0.40) and Xi (-0.52, 95% CI - 0.67 to - 0.38) revealed shorter operative times; however, under random-effects models these differences were not statically significant due to substantial heterogeneity. Heterogeneity (I² ≈ 84%) attenuated these effects. For ischemia time, Hugo RAS (-0.88, 95% CI - 1.45 to - 0.30) and Xi (-0.58, 95% CI - 0.73 to - 0.44) outperformed Si, though differences lost significance under random-effects (I² >90%). No significant differences were found for length of stay, blood loss, or R.E.N.A.L. nephrometry scores, although ranking differences were observed. Preoperative outcomes were revealed a comparable outcome using emerging robotic system with the established system. Favourable trends in operative and ischemia times were showed in some platforms; however, these differences were not vigorous under random-effects models and are limited by substantial heterogeneity. This raised the need for long-term, comparative follow-up studies, as the current evidence remains elementary.
22 May 2026
Read appraisal →Chinese medical journal
Estimating minimal, moderate, and marked clinically important differences for patient reported outcome measure in randomised controlled trial
BACKGROUND: Patient-reported outcome measures (PROMs) are increasingly used in clinical trials, yet thresholds that define clinically important difference (CID) within patients and treatment effects beyond placebo remain inconsistently reported, limiting its utility in clinical research and practice. Using chronic pelvic pain and its core PROM as a worked example, the study aims to present a structured framework for CID thresholds that separates within-group change from between-group difference in treatment effect, each further stratified as minimal, moderate, and marked. METHODS: We used data from a multicenter randomized controlled trial of acupuncture vs . sham acupuncture in 440 men with chronic prostatitis (CP)/chronic pelvic pain syndrome (CPPS) conducted from October 2017 to April 2019. National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) served as the PROM and the Patient Global Impression of Change (PGI-C) as the anchor. CIDs were estimated using a linear mixed-effects model to assess changes in NIH-CPSI scores across PGI-C categories. RESULTS: At the end of treatment, 12.3% (51/414) participants reported no change, 34.1% (141/414) slight improvement, 32.1% (133/414) moderate improvement, and 19.6% (81/414) marked improvement; and 1.9% (8/414) reported worsening. The estimated Clinically important within-group difference (CIDs within-group ) in NIH-CPSI total score was 4.6 points for minimal, 6.0 points for moderate, and 7.3 points for marked improvement. The corresponding Clinically important between-group difference (CIDs between-group ) were 1.4, 2.7, and 4.1 points, respectively. CONCLUSIONS: In this methodological study, we proposed a pragmatic and scalable operational framework to derive thresholds for minimal, moderate, and marked CIDs. By explicitly distinguishing CIDs within-group and CIDs between-group , the approach clarifies two frequently conflated terms that serve distinct purposes in interpretation and decision-making. This framework offers benchmarks to strengthen inference on treatment response, trial design, and guideline decision thresholds.
21 May 2026
Read appraisal →Lancet (London, England)
Efficacy and safety of cefepime-nacubactam and aztreonam-nacubactam compared with imipenem-cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial
BACKGROUND: Nacubactam (OP0595) is a newly developed diazabicyclooctane β-lactamase inhibitor used in combination with cefepime or aztreonam. We assessed the efficacy and safety of cefepime-nacubactam and aztreonam-nacubactam versus imipenem-cilastatin in complicated urinary tract infection (cUTI) or acute uncomplicated pyelonephritis. METHODS: The Integral-1 global, phase 3, multicentre, randomised, double-blind study recruited adults (aged ≥18 years) with cUTI or acute uncomplicated pyelonephritis at 79 sites in Bulgaria, China, Czech Republic, Estonia, Georgia, Japan, Latvia, Lithuania, and Slovakia. Patients were randomly assigned (2:1:1) to receive intravenous cefepime (2 g) plus nacubactam (1 g), aztreonam (2 g) plus nacubactam (1 g), or imipenem (1 g) plus cilastatin (1 g) every 8 h for 5-14 days. Randomisation was stratified by diagnosis and geographical region. The primary endpoint was the proportion of patients achieving composite clinical and microbiological success at test of cure in the microbiological modified intention-to-treat population-all patients who were randomly assigned, received any amount of the study drug, and had a baseline qualifying pathogen that was susceptible to imipenem and meropenem. The prespecified non-inferiority margin was more than 15 percentage points difference; the superiority margin was more than zero percentage points difference, for the lower bound of the two-sided 95% CI for imipenem-cilastatin. Safety was assessed in all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, NCT05887908. FINDINGS: Between May 22, 2023, and Nov 26, 2024, 614 patients were randomly assigned and 431 were included in the primary efficacy analysis (cefepime-nacubactam [n=214], aztreonam-nacubactam [n=112], or imipenem-cilastatin [n=105]); 228 patients (53%) were male and 203 (47%) were female. The primary endpoint was achieved by 176 (82%) of 214, 81 (72%) of 112, and 64 (61%) of 105 patients in the cefepime-nacubactam, aztreonam-nacubactam, and imipenem-cilastatin groups, respectively. The percentage difference in the success rate versus imipenem-cilastatin was 21·3% (95% CI 10·9 to 32·0) for cefepime-nacubactam (non-inferior and superior), and 11·4% (-1·2 to 23·7) for aztreonam-nacubactam (non-inferior). Treatment-emergent adverse events were reported in 100 (33%) of 306, 45 (30%) of 152, and 65 (43%) of 150 patients in the cefepime-nacubactam, aztreonam-nacubactam, and imipenem-cilastatin groups, respectively. No treatment-related deaths occurred. INTERPRETATION: Cefepime-nacubactam and aztreonam-nacubactam are potential treatment options for Gram-negative cUTI and acute uncomplicated pyelonephritis, including infections caused by antimicrobial-resistant strains. FUNDING: Meiji Seika Pharma and Japan Agency for Medical Research and Development.
18 May 2026
Read appraisal →World journal of urology
Comparative study on the efficacy of large language models (LLMs) in health management for patients with urological and andrological diseases: a multidimensional quality evaluation and applicability analysis
PURPOSE: This study aims to evaluate the efficacy of large language models (LLMs) in health management for urological and andrological conditions by comparing two Chinese LLMs: DeepSeek and Kimi. METHODS: The responses of DeepSeek and Kimi to 30 questions on six urological and andrological diseases were quantitatively assessed using quality assessment tools, expert assessments, and readability metrics. RESULTS: In quality assessments, DeepSeek outperformed Kimi in only two instances: responses to "What are the surgical options for kidney stones?" (PEMAT-AI: P = 0.012; DISCERN-AI: P = 0.024) and "What are the treatment modalities for bladder cancer?" (PEMAT-AI and DISCERN-AI: P < 0.001). Expert assessments revealed that DeepSeek demonstrated superior accuracy and safety compared to Kimi only in addressing "Dietary considerations for kidney stone patients" (accuracy: P < 0.001; safety: P = 0.02). No statistically significant differences were found in quality assessments or expert assessments between the models for disease-specific categories. However, Kimi outperformed DeepSeek in readability evaluations. CONCLUSION: Both DeepSeek and Kimi exhibit substantial efficacy and clinical applicability in managing urological and andrological diseases. To enhance their practical use, Kimi requires improvements in accuracy and safety, while DeepSeek should focus on improving readability.
18 May 2026
Read appraisal →JMIR medical informatics
From Flow to Feature Using a Proof-of-Concept Spectral-Driven Machine Learning Approach Using Smart Urinary and Drainage Catheter Systems: Algorithm Development and Validation
BACKGROUND: Current urinary and drainage catheter systems collect fluids for visual inspection or manual sampling, offering limited diagnostic value while being labor-intensive and prone to error. Machine learning (ML) has the potential to automate the analysis of these fluids. However, existing methods rely on complex preprocessing steps, which hinder real-time analysis. OBJECTIVE: We aim to develop and evaluate a fully automated, real-time diagnostic approach for smart urinary and drainage catheter systems by leveraging spectral data and ML to differentiate pathological from healthy excreted fluids without the need for manual preprocessing. METHODS: This study proposes a novel, fully automated approach for smart urinary and drainage catheter systems that uses spectra and ML to extract features from excreted fluids, enabling real-time analysis directly. A total of 454 surgical drainage fluid samples (from 181 patients) and 401 urine catheter samples (from 168 patients) were analyzed using smart catheters and drains equipped with compact mini-spectrometer sensors. The collected spectral data were fed into 3 different ML models: a random forest, a partial least squares discriminant analysis regression, and a convolutional neural network (CNN). Each model aimed to extract features and differentiate between pathological and healthy urine and drainage samples based on the various biomarkers available from previously conducted laboratory analyses. RESULTS: All 3 approaches (random forest, partial least squares discriminant analysis regression, and CNN) achieved promising results, demonstrating the potential of the overall approach. In particular, the CNN models trained on the drainage biomarkers hemoglobin and bilirubin achieved the best results. Matthews correlation coefficient scores of 0.83 and 0.81 were obtained for hemoglobin and bilirubin, respectively, when differentiating between pathological and healthy samples using the extracted spectral features. CONCLUSIONS: This work demonstrates the potential of spectral-driven ML for smart urinary and drainage catheter systems. This approach offers a real-time, noninvasive method for analyzing excreted fluids, paving the way for improved diagnostics and personalized patient care. Further research will explore the optimal ML model for this application.
17 May 2026
Read appraisal →International journal of cancer
Testicular cancer in intersex individuals: A systematic review for clinical practice
The objective of this systematic review was to identify the evidence of testicular cancer risk for people with intersex conditions. This assessment is hoped to help refine risk stratification tools for assessing gonadal malignancy risk and guide the development of more robust evidence-based management strategies. The literature was searched in Ovid MEDLINE, Embase, and Cumulative Index of Nursing and Allied Health using a search string developed by a multidisciplinary team. The protocol was registered at Prospective Register of Systematic Reviews as CRD42021231313. A total of 3608 articles were found. After selection, 301 publications were included (1215 individuals). The results identified significant evidence that pre-pubertal gonadectomy may be linked to lower rates of malignant gonadal changes for patients with partial gonadal dysgenesis, Turner's syndrome with Y-chromosome material, complete androgen insensitivity, partial androgen insensitivity, and patients with ovotestis/es. The evidence was not significant for patients with complete gonadal dysgenesis, Klinefelter syndrome, nor WT1-related syndromes. Specific cancer outcomes were unable to be assessed due to small sample sizes and thus it is unknown if clinically significant cancer outcomes are meaningfully altered by pre-pubertal gonadectomy. Importantly, the quality of data on the topic of gonadal malignancy in intersex patients with testicular tissue was determined to be poor overall. The quality was relatively more robust regarding the conditions of Complete Androgen Insensitivity, Klinefelter syndrome, and patients with ovotestis/es. More high-quality research is needed to draw specific conclusions on the risks and benefits of performing pre-pubertal gonadectomy for intersex patients. When counseling these patients, clinicians should be transparent regarding the paucity of data supporting pre-pubertal gonadectomy.
17 May 2026
Read appraisal →Scientific reports
The impact of tissue detection on diagnostic artificial intelligence algorithms in prostate digital pathology
Tissue detection is a crucial first step in most digital pathology applications. By applying image segmentation algorithms, all tissue is delineated and background discarded from further analyses, improving both computational efficiency and analytical results. Details of the segmentation algorithm are rarely reported, and there is a lack of studies investigating the downstream effects of a poor segmentation algorithm. Disregarding tissue detection quality could jeopardize patient safety if diagnostically relevant parts of the specimen are excluded from analysis in clinical applications. This study aims to determine whether performance of downstream tasks is sensitive to the tissue detection method, and to compare the performance of a classical and an AI-based tissue detection approach. To this end, we trained an AI model for Gleason grading of prostate cancer in whole slide images (WSIs) using two different tissue detection algorithms: thresholding (classical) and UNet++ (AI). A total of 33,823 WSIs scanned on seven digital pathology scanners were used to train the segmentation AI model. The downstream Gleason grading algorithm was trained and tested using 70,524 WSIs from 13 clinical sites scanned on 13 different scanners. On the slides where tissue could be detected by both algorithms, no significant difference in overall Gleason grading performance was observed. There was a decrease from 118 (0.43%) to 24 (0.09%) fully undetected tissue samples when switching from thresholding-based tissue detection to AI-based, suggesting this AI model may be more reliable than the classical model for avoiding total failures on slides with unusual appearance. Moreover, tissue detection dependent clinically significant variations in AI grading were observed in 3.5% of malignant slides, highlighting the role of tissue detection for optimal clinical performance of diagnostic AI.
15 May 2026
Read appraisal →BMJ open
Performance of large language models (GPT-5.2, Gemini 3 Pro, Claude Sonnet 4.6 and Grok 4.1) on the Fellowship of The Royal College of Surgeons Urology Part A examination.
OBJECTIVES: To assess and compare the performance of four contemporary frontier large language models (LLMs)-GPT-5.2 (OpenAI), Gemini 3 Pro (Google DeepMind), Claude Sonnet 4.6 (Anthropic) and Grok 4.1 (xAI)-on a simulated Fellowship of The Royal College of Surgeons Urology (FRCS(Urol)) Part A examination, evaluating overall accuracy, subspecialty-level performance, output consistency and response time. DESIGN: Controlled comparative evaluation study using a standardised simulation framework with repeated independent testing runs per model. SETTING: All models were accessed via their respective consumer-facing interfaces. No clinical setting or patient data were involved. Testing was conducted under uniform conditions with conversational memory disabled across all sessions. PARTICIPANTS: Four large language models were evaluated. No human participants were involved. Models were selected to represent the current frontier of publicly accessible LLMs from four distinct commercial developers. No models were excluded following selection. INTERVENTIONS: Each model was presented with 240 FRCS (Urol) Part A single best answer questions, mapped to the Joint Committee on Intercollegiate Examinations' Urology Syllabus Blueprint (2023). A standardised prompt was delivered at the start of each session. Each model completed five independent examination runs. No fine-tuning or system-level modification was applied to any model. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcome was overall examination accuracy for each model, benchmarked against an indicative pass threshold for the FRCS (Urol) Part A examination. Secondary outcomes were performance across 18 individual urology subspecialty topics; response time reported as mean total and per-question elapsed time; and consistency of performance quantified by SD and 95% CIs derived from a sequential Monte Carlo sampling procedure. All outcomes were prospectively planned and fully measured as specified. RESULTS: Three of four models exceeded the indicative 74% pass threshold: Gemini 3 Pro (82.4%±0.9%; 95% CI 81.3 to 83.6%), Claude Sonnet 4.6 (79.3%±1.1%; 95% CI 77.9 to 80.6%) and GPT-5.2 (76.1%±2.4%; 95% CI 73.1 to 79.1%). Grok 4.1 failed (70.4%±0.6%; 95% CI 69.6 to 71.2%), with its entire CI below 74%. All models completed the assessment in under 3 min. Strong performance was observed in research methodology (90-98%) and andrology (92-98%), with the weakest results in paediatric urology (38.7-54.7%) and testicular cancer (48.2-67.3%). Substantial within-model output instability was identified across several domains, most notably GPT-5.2 in female urology (SD±22.8%) and anatomy (SD±14.2%). CONCLUSIONS: Three of four frontier LLMs achieved scores consistent with passing the FRCS (Urol) Part A examination, representing a substantial advance since ChatGPT-3.5. Aggregate accuracy alone, however, obscures important subspecialty weaknesses and output instability. LLMs should be regarded as adjunctive revision aids rather than authoritative knowledge sources and always used alongside expert-led teaching. Future work should evaluate performance on Part B and viva-style assessments.
15 May 2026
Read appraisal →Journal of robotic surgery
NeuroSAFE-guided robot-assisted radical prostatectomy versus standard RARP: systematic review and meta-analysis of comparative studies
Prostate cancer is the most common male malignancy, and although robotic-assisted radical prostatectomy (RARP) is widely used, urinary incontinence and erectile dysfunction remain significant issues. NeuroSAFE, an intraoperative frozen section technique aimed at optimizing nerve preservation without compromising cancer control, is increasingly used, but its overall impact on outcomes remains unclear.To systematically evaluate the effectiveness and safety of the NeuroSAFE technique during RARP, comparing functional recovery and oncologic outcomes with non-NeuroSAFE approaches.This systematic review and meta-analysis followed PRISMA 2020 guidelines and was registered in PROSPERO (CRD420251032774). A comprehensive search of Embase, MEDLINE, and ClinicalTrials.gov (March, 2026) identified studies reporting oncologic and/or functional outcomes in men undergoing RARP with NeuroSAFE. Two reviewer teams independently conducted study selection, data extraction, and risk-of-bias assessment using ROBINS-I tool. Random-effects meta-analyses estimated pooled odds ratios (ORs) with 95% confidence intervals (CIs). Heterogeneity was quantified with the I2 statistic, and publication bias was evaluated using Egger's test.Thirteen studies (2 randomized controlled trials and 11 observational cohorts) comprising 22,183 patients met the inclusion criteria. NeuroSAFE was associated with significantly improved postoperative erectile function (OR 2.00; 95% CI 1.46-2.74) and urinary continence recovery (OR 1.36; 95% CI 1.05-1.76). Positive surgical margins were significantly reduced in the NeuroSAFE group (OR 0.73; 95% CI 0.59-0.89). No differences in biochemical recurrence were observed (OR 0.81; 95% CI 0.43-1.56). Heterogeneity was substantial for some outcomes, and most nonrandomized studies carried a serious risk of bias, which limits causal inference.This systematic review and meta-analysis, including randomized evidence, demonstrates that NeuroSAFE is a safe and effective intraoperative strategy that is associated with improved erectile function, enhanced continence recovery, and negative surgical margins without compromising oncologic outcomes. These findings support integrating NeuroSAFE into surgical decision-making for patients undergoing RARP, particularly when nerve preservation can be achieved without compromising oncologic outcomes.In this study, we compared a surgical approach that uses real-time analysis during prostate cancer surgery with the standard technique. This method helps surgeons decide how much tissue to preserve while the operation is still ongoing. We found that this approach is safe and may improve recovery of urinary continence and sexual function, while also reducing the risk of leaving cancer behind, without compromising cancer control.
14 May 2026
Read appraisal →World journal of urology
Complications of thulium fiber laser lithotripsy: a systematic review and meta-analysis by the EAU-YAU endourology and urolithiasis working group
BACKGROUND: Thulium Fiber Laser (TFL) has emerged as a promising alternative to Holmium: YAG for lithotripsy, yet its safety profile remains fragmented across various trials. This study aims to synthesize available evidence to determine the pooled complication rates associated with TFL lithotripsy . METHODS: A systematic review was conducted following PRISMA guidelines. We searched PubMed, Cochrane CENTRAL, and ClinicalTrials.gov for studies reporting complications of TFL in adult patients with urolithiasis. The primary outcome was the overall complication rate. Secondary outcomes included Clavien-Dindo grading, specific adverse events (fever, sepsis, injury), and stone-free rate (SFR). A random-effects meta-analysis was performed using the Freeman-Tukey double-arcsine transformation. RESULTS: Thirty-eight studies involving 3,329 patients were included. The pooled overall complication rate was 10.42% (95% CI: 8.01%-13.10%; I²=81.9%). Major complications (Clavien-Dindo III-V) were rare, with a pooled rate of 1.19% (95% CI: 0.68%-1.84%). Specific event rates included fever (2.45%), ureteral injury (1.37%), bleeding (1.07%), urosepsis (0.77%), ureteral strictures (0.70) and acute pyelonephritis (0.59%). Meta-regression identified operative time as a significant predictor of complications (p = 0.041), whereas stone size was not (p = 0.358). Subgroup analysis showed higher complication rates in pure renal stone treatments (13.83%) compared to ureteral stones (10.64%). The pooled Stone-Free Rate (SFR) was 87.61% (95% CI: 83.61%-91.12%). CONCLUSION: Thulium Fiber Laser lithotripsy demonstrates a pretty favorable safety profile with a very low incidence of high-grade complications (< 1.2%) and high efficacy.
14 May 2026
Read appraisal →Scientific reports
Deep learning-based automatic field of view planning for prostate MRI in oblique coronal and oblique axial planes
Accurate field-of-view (FoV) prescription in oblique coronal and axial planes is essential for high-quality prostate MRI but remains operator-dependent and variable. We developed and evaluated a ResNet-based deep learning framework for automated FoV planning. In this retrospective multicenter study, FoV prescriptions were annotated on PI-CAI dataset. Three readers assessed intra- and inter-rater variability to establish reference consistency. Three neural network variants were trained on 1,474 examinations from PI-CAI dataset (2012-2021), and the optimal model was selected by internal validation. Generalizability and clinical utility were tested on three external cohorts totaling 530 examinations (2021-2024) using a non-inferiority design. The selected model achieved non-inferior performance for slice positioning, with differences ranging from 0.16 ± 0.99 to 0.37 ± 0.48. Across sites, FoV overlaps ranged from 82.4 ± 4.1% to 88.7 ± 6.0%, and the angle differences between predicted and reference planes were 4.66 ± 4.89° (Site I), 3.46 ± 2.80° (Site II), and 2.99 ± 2.90° (Site III). Clinical utility was high at all sites, with acceptability rates of 97.9%, 97.7%,98.8%, 98.1% and 98.1% for Site I (Raters 1-5), 95.7%, 97.8%, 100%, 95.7% and 97.8% for Site II (Raters 1-5), and 100% for all raters at Site III. These findings demonstrate the feasibility of automated FoV positioning for prostate MRI and indicate excellent clinical utility.
14 May 2026
Read appraisal →Pediatric surgery international
Effect of anticholinergics vs. alpha-1 blockers vs. combination therapy on bladder function in patients with posterior urethral valve after transurethral fulguration: a pilot randomized controlled trial
PURPOSE: To identify preliminary efficacy signals of anticholinergics, alpha-1 blockers, and their combination on bladder and renal function in boys with bladder dysfunction following posterior urethral valve (PUV) ablation, and to assess the feasibility of conducting a definitive randomized, controlled trial. STUDY DESIGN: In this single-center, prospective, randomized pilot trial boys under 12 years who had undergone cystoscopic valve ablation were randomized into three groups: anticholinergic therapy (Group I), alpha-1 blocker therapy (Group II), and combination therapy (Group III). The study was designed to detect within-group preliminary efficacy signals in urodynamic parameters following 6 months of pharmacotherapy. Secondary outcomes included changes in patient-reported symptom scores, renal function, and feasibility metrics. Between-group comparisons were performed as exploratory analyses. Feasibility and safety outcomes were analyzed in the intention-to-treat population, while efficacy analyses were conducted in participants who received intervention and had evaluable baseline and follow-up data. RESULTS: Thirty-five eligible patients were randomized (Group I, n = 12; Group II, n = 11; Group III, n = 12). and their clinical and biochemical analyses at baseline were recorded. Two deaths in Group II occurred prior to baseline urodynamics and pharmacotherapy initiation; efficacy analyses, therefore, included 33 patients (Group I, n = 12; Group II, n = 9; Group III, n = 12) with evaluable data. Urodynamic evaluation demonstrated favourable within-group trends: Group I showed a significant improvement in voided volume, while changes in voiding time, cystometric capacity (CC), static compliance, and maximum detrusor pressure (Pdetmax) were favourable but not uniformly statistically significant. Group II showed modest, favourable effects on Qmax, Time@Qmax, CC, and Pdetmax, with wide confidence intervals and no clear significant changes across most UDS measures. Group III demonstrated the most consistent favourable pattern, particularly for CC and Pdetmax, although most confidence intervals overlapped the null. Baseline-adjusted exploratory analyses did not demonstrate statistically significant between-group differences. Symptom scores improved across all groups. Feasibility outcomes were robust, with 81% recruitment, 91% urodynamic study completion, and 94% participant retention. CONCLUSION: This pilot trial demonstrates the feasibility of conducting urodynamic-guided pharmacotherapy studies in young boys with PUV-related bladder dysfunction. The observed within-group efficacy signals across all treatment arms-particularly with combination therapy-are hypothesis-generating and provide effect size and variability estimates to inform the design of a definitive randomized controlled trial.
13 May 2026
Read appraisal →Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide
PURPOSE: In patients who received enzalutamide, we characterized the development of radiographic progression (rPD) without prostate-specific antigen (PSA) rise or progression in metastatic hormone-sensitive prostate cancer (mHSPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC). METHODS: We conducted a post hoc analysis in two phase III trials (N = 2,551; ARCHES [ClinicalTrials.gov identifier: NCT02677896]; PROSPER [ClinicalTrials.gov identifier: NCT02003924]) for co-occurrence of rPD ± Prostate Cancer Working Group 2/3-defined PSA progression, and rPD ± any PSA rise from baseline/nadir by treatment. Kaplan-Meier methods were used for overall survival (OS) outcomes. RESULTS: In ARCHES, 3.5% and 8.5% of 574 patients with mHSPC treated with enzalutamide plus androgen-deprivation therapy (ADT) had no PSA rise or PSA progression at rPD, respectively. Of 79 patients with rPD who received enzalutamide plus ADT, 25.3% had no PSA rise and 62.0% did not meet PSA progression criteria compared with 7.4% and 38.3% of 188 patients with rPD treated with ADT alone, respectively. In PROSPER, 4.4% and 10.3% of 933 patients with nmCRPC treated with enzalutamide plus ADT had no PSA rise or PSA progression, respectively, at rPD. However, of 187 patients with rPD who received enzalutamide plus ADT, 21.9% had no PSA rise and 51.3% did not meet PSA progression criteria compared with 3.6% and 18.8% of 224 patients treated with placebo/ADT, respectively. Liver metastases were >5-fold higher in enzalutamide-treated patients with rPD events versus control, although sample size was small. Compared with no rPD, enzalutamide-treated patients with rPD ± PSA rise or progression had worse OS. CONCLUSION: Given the frequent discordance and poor prognosis of imaging-based progression in the absence of PSA changes during enzalutamide treatment in mHSPC and nmCRPC, periodic surveillance using imaging is recommended.
12 May 2026
Read appraisal →Physics in medicine and biology
Multi-model study of fast VMAT segment dose calculation with deep learning.
Objective.Deep learning (DL) methods enable photon dose calculation under two main coordinate representations: Beam's Eye View (BEV) and patient coordinates. We evaluate dose calculation accuracy and speed under these coordinate paradigms and with representative DL models within a unified dataset and pipeline, and introduce two lightweight models for fast photon dose calculation.Approach.Planning computed tomography (CT) scans and volumetric modulated arc therapy plans from 24 prostate cancer patients were used. Monte Carlo simulation generated 5940, 540, and 3053 segment doses for training (11 patients), validation (3), and testing (10), respectively. For BEV, we used a combination of convolutional neural network (CNN) and convolutional long short-term memory network (ConvLSTM) called CNN-ConvLSTM, a CNN-Mamba combination (CNN-Mamba), a transformer-based architecture (DoTA), and a cascaded 3D UNet (C3D). These were trained on CT and segment-projection BEV cuboids. For patient coordinates, the DeepDose individual segment dose prediction framework implemented with C3D (DeepDose-C3D) was trained on cropped CT volumes with four physical inputs. Segment and plan dose accuracy were assessed using local gamma passing ratesγPR(2%/3 mm and 1%/3 mm) and dose-volume histogram metrics. Dose calculation times (inference plus pre/post-processing) were measured on three different graphics processing unit (GPUs).Results.All five models achieved mean localγPRvalues⩾91.0% (2%/3 mm) for segment doses and⩾99.0% (1%/3 mm) for plan doses. Mean per-segment dose calculation times were 79, 67, 298, 490, 356 ms for CNN-ConvLSTM, CNN-Mamba, DoTA, C3D, and DeepDose-C3D, respectively. On the latest-generation GPU available, the corresponding per-plan (average 305 segments) dose calculation times were 5.5, 6.2, 33.6, 38.7, 35.4 s.Significance.Both BEV- and patient-coordinate DL methods achieved accurate photon plan dose calculation, with BEV-based approaches showing more robust segment performance. CNN-ConvLSTM and CNN-Mamba retain comparable accuracy at lower computational cost, enabling fast photon dose calculation.
12 May 2026
Read appraisal →Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace
Prevalence of urinary incontinence in patients with chronic cough: a systematic review
Chronic cough-related diseases increase the risk of urinary incontinence (UI) due to repeated intra-abdominal pressure affecting the pelvic floor. Existing studies focus on specific diseases rather than UI as a broader consequence. To determine the prevalence of UI in patients with chronic cough-related diseases and compare it with the prevalence in healthy populations. A systematic review was conducted using Medline, Embase, Cochrane, OVID, Scopus, ProQuest, PEDro, and EBSCO. Two independent reviewers screened studies using predefined criteria in a Microsoft Excel spreadsheet. Only prevalence studies were included. Data were extracted, synthesized, and assessed using the GRADE approach for evidence quality and the STROBE checklist for reporting quality. Prevalence estimates varied widely based on demographic characteristics. UI prevalence ranged from 2.2% to 45% in pediatric patients, 30.4% to 74% in adult women, and 2.4% to 39% in adult men. The quality of evidence was low, while reporting quality was acceptable. UI is a common complication in patients with chronic cough, with a higher prevalence than in healthy populations. Due to the stigma surrounding urogenital disorders, clinicians should actively inquire about UI during patient history-taking and refer affected individuals for appropriate treatment.
11 May 2026
Read appraisal →World journal of urology
Quantifying ergonomic challenges for urologists operating flexible ureteroscopes through artificial intelligence-based posture estimation
PURPOSE: The ergonomic challenges faced by surgeons during flexible ureteroscopy have yet to be thoroughly evaluated using objective methods. However, robot-assisted ureteroscopy has emerged as a promising treatment for urinary stones. The present study quantitatively assesses operative posture during transurethral ureteroscopy via an artificial intelligence-based posture estimation framework, and identifies kinematic differences associated with surgical expertise. METHODS: Expert and novice urologists performed standardized flexible ureteroscopic tasks in a simulated transurethral ureteroscopy environment using kidney phantoms containing artificial stones. Upper-body movements were continuously video-recorded and joint coordinates of the shoulders, elbows, and wrists were extracted using an artificial intelligence-based pose estimation system. Kinematic parameters were quantitatively analyzed and compared between groups. RESULTS: Experts completed observation of the entire renal pelvis significantly faster than novices (median 58 vs. 102 s, p < 0.001). Accumulated travel distance was markedly less in experts for the left shoulder (125 vs. 300 cm, p < 0.001), right elbow (324 vs. 1035 cm, p = 0.028), left elbow (349 vs. 772 cm, p = 0.019), and left wrist (729 vs. 3798 cm, p < 0.001). Experts had smaller movement areas at the left shoulder (6.29 vs. 40.5 cm2, p < 0.001) and right elbow (17.3 vs. 281 cm2, p = 0.040), and reduced movement ranges across multiple joints. Their angle fluctuation ranges were also narrower for the right shoulder (32.0 vs. 76.3°, p = 0.028) and left elbow (70.4 vs. 122.4°, p < 0.001). CONCLUSIONS: The artificial intelligence-based posture analysis objectively demonstrated ergonomic advantages associated with surgical expertise during flexible ureteroscopy and revealed persistent ergonomic risks to the wrist and elbow.
11 May 2026
Read appraisal →Journal for immunotherapy of cancer
Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancer
BACKGROUND: Grade group 5 (GG5) prostate cancer (PCa) carries a less favorable prognosis after standard-of-care (SOC) therapy, necessitating novel therapeutic approaches. High-dose rate brachytherapy (HDRBT) and androgen deprivation therapy (ADT) may modulate immune response in GG5 PCa, particularly in tumors with increased immune content. This study evaluated whether the addition of nivolumab to SOC was associated with improved disease control in patients with high-volume GG5 PCa, including those with oligometastatic disease. METHODS: In this non-randomized phase II trial, 31 patients with localized or oligometastatic GG5 PCa and >30% positive biopsy cores were evaluated between September 2018 and April 2021. Patients received four doses of nivolumab (240 mg every 2 weeks) beginning 4 weeks prior to HDRBT, alongside ADT, HDRBT, and external beam radiation. The primary endpoint was to evaluate whether the 2-year freedom from biochemical recurrence (FFBR) rate would exceed a prespecified historical control rate of 75%. RESULTS: Among the 31 patients, the median follow-up was 38.8 months (IQR 31.0-46.5 months). The addition of nivolumab to SOC RT with ADT was associated with a 2-year FFBR rate of 90.3% (95% CI 74.3% to 98.0%) (median FFBR not reached), exceeding the prespecified historical control rate of 75% (one-sided p value from binomial test=0.024). Definitive and probable nivolumab-related toxicity included 6.3% acute grade 2 and 6.3% acute grade 3 adverse events (AEs), with no grade 4+ AEs observed. A higher Decipher immunosuppression score at diagnosis correlated with early pathologic response (p=0.005) and was independently associated with time to metastatic failure (p=0.044). CONCLUSIONS: Nivolumab combined with SOC was associated with encouraging FFBR in this high-risk GG5 PCa population and may represent a promising therapeutic intensification strategy. The Decipher immunosuppression score may serve as a predictive biomarker for response. These findings warrant further investigation in randomized trials.
11 May 2026
Read appraisal →Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
Raman spectroscopy with machine-learning classification for the prediction of stereotactic radiotherapy induced treatment toxicity in high-risk localised prostate cancer
Radiotherapy can lead to late-onset toxicity, to varying extents between individuals due to differences in radiosensitivity. Predicting which patients are most at risk is key to augmenting the therapeutic window. However, the underlying biological mechanisms remain poorly understood, and current experimental methods often lack clinical applicability. This study employs Raman spectroscopy to analyse biochemical profiles in peripheral lymphocytes and plasma, aiming to monitor radiotherapeutic response and predict intrinsic radiosensitivity in high-risk localised prostate cancer patients treated with stereotactic radiotherapy. Partial-least squares discriminant analysis classification of Raman spectra at baseline (n = 20) from post-hormone therapy (n = 19), mid-treatment (pre-4th fraction; n = 21) and 3-months after treatment (n = 18) returned mean area under the curve values ranging from 0.88 to 0.93. Ensemble classifiers applied to imbalanced late toxicity datasets (grade 0-1, n = 16; grade 2+, n = 4) yielded mean F1 scores of 0.74 (random forest, lymphocytes) and 0.69 (AdaBoost, plasma); metrics based on best performing model for minority-class. Classical least squares lymphocyte and plasma toxicity models identified major concentration differences in amino acids, proteins, lipids, DNA and related biomolecules (p < 0.05). These findings demonstrate the potential of Raman spectroscopy as a minimally invasive, objective tool for classifying blood-based biochemical profiles across radiotherapy treatment time points and distinguishing patients with late grade 0-1 and grade 2+ toxicity.
10 May 2026
Read appraisal →European journal of cancer (Oxford, England : 1990)
Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12.
BACKGROUND: Androgen-deprivation therapy (ADT) plus radiotherapy is a standard of care for men with high-risk localized prostate cancer (PC). Adding docetaxel in this setting demonstrated better relapse-free survival (RFS) but not survival. Few data are available on relapse patterns. Our aim was to investigate whether different patterns of relapses exist in men with high-risk localized PC. PATIENTS AND METHODS: Prospective data from the GETUG12 phase 3 randomized controlled trial comparing ADT alone vs ADT + docetaxel and estramustine (DE) was examined. RFS (main endpoint) was analysed using parametric survival models and second event-free survival (SEFS) defined from biochemical progression (BP) was analysed using a competing-risk approach. RESULTS: Overall, 413 patients were randomized from 2002 to 2006, 206 treated with ADT and 207 with ADT+DE, in addition to local treatment. First analysis showed that the piecewise-exponential model with two time-intervals ([0-3[; ≥3 years) was the model that best characterized RFS with no time-dependent effect of risk factors and treatment. Second analyses limited to patients with a BP showed that the risk of a second event was significantly lower in patients with a longer time-interval from randomization to BP (hazard ratio (HR≥ 3 versus < 3 years): 0.49 [95% CI 0.30-0.79]). In competing-risk analysis, a significant and protective effect of this time-interval was observed for metastases (sub-HR≥ 3 versus < 3 years: 0.41 [0.23-0.73] accounting for salvage treatment. CONCLUSION: Time-interval from randomization to BP is a major prognostic factor for developing local or distant recurrences for patients with high-risk localized PC.
10 May 2026
Read appraisal →Current urology reports
Artificial Intelligence in Urologic Documentation: A Review of Emerging Capabilities and the Ongoing Need for Human Oversight
PURPOSE OF REVIEW: Clinical documentation continues to expand in volume and complexity, spanning outpatient encounters, inpatient summaries, patient-portal communications, and educational materials. These growing demands contribute to clinician burden and reduce time available for direct patient care. Artificial intelligence (AI) has emerged as a potential strategy to streamline documentation workflows. This review evaluates current AI applications in clinical documentation, with illustrative examples from urologic practice. RECENT FINDINGS: Ambient AI scribes can capture the bulk of outpatient encounters and generate structured draft notes that clinicians edit rather than write de novo. Large language models have shown promise in assisting with inpatient documentation and discharge summaries, often producing drafts that are coherent, readable, and shorter than physician-authored text. AI tools can also simplify patient education materials and translate dense radiology reports into accessible language. Across these domains, however, studies consistently demonstrate that AI-generated content remains vulnerable to factual errors, omissions, hallucinations, and misaligned emphasis, reinforcing the need for clinician oversight. Overall, emerging evidence supports a complementary relationship between clinicians and AI. Used as supervised drafting aids rather than autonomous authors, AI tools have the potential to ease documentation burden and create more time for direct patient care without diminishing the clinician's role in shaping the medical record.
10 May 2026
Read appraisal →Biomedical physics & engineering express
Dosimetric evaluation of simultaneous multi-energy (2-18 MV) and intensity optimization for IMRT and VMAT.
Objective.This study aimed to develop and evaluate a framework for the simultaneous optimization of beam fluence and multiple photon energies beyond dual-energy configurations for intensity modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT), with the goal of improving treatment plan quality and normal tissue sparing.Approach.An Elekta Versa HD linear accelerator (linac) was modeled using the BEAMnrc/EGSnrc Monte Carlo platform to simulate 2 MV, 4 MV, and 6 MV photon beams, complemented with measured beam data for 10 MV and 18 MV. A custom MATLAB-based framework was developed to perform simultaneous optimization of energy and fluence, allowing energy weighting of individual beamlets. A total of 12 various energy configurations including single (SE), dual (DE), triple (TE), and quadruple (QE)-energy combinations for IMRT and VMAT were generated for thirteen prostate cancer patients. Plans were evaluated using dose-volume histograms, homogeneity index, conformity index, and organ-at-risk (OAR) dose metrics.Main results.Gamma analysis confirmed the high degree of agreement between measured and simulated beam data, which validated our Monte Carlo linac model. Target coverage remained comparable across all energy configurations. Compared with 6 SE, multi-energy (ME) IMRT and VMAT achieved superior OAR sparing, with the greatest benefits for bladder and rectum in the 5-40 Gy range. TE-IMRT reduced bladder and rectal mean doses by up to 1.6 Gy, with V10 reductions of ∼8%; on average, mean doses were reduced by 0.9 Gy (p= 0.001) and 1.0 Gy (p= 0.001). For VMAT, the 6&18 DE-VMAT plan yielded the largest sparing, lowering bladder and rectal mean doses by ∼1.0 Gy. Relative to 10 SE, all ME plans achieved equal or lower OAR doses, with TE-IMRT and 6&18 DE-VMAT showing the most consistent benefit, reducing mean doses to the bladder, rectum, right femoral head, and left femoral head by up to 1.26, 0.77, 0.6, and 0.55 Gy, respectively.Significance.This study presents the first assessment of the feasibility and potential clinical value of simultaneous optimization of beam intensity and more than two photon energies for IMRT and VMAT plans, producing optimized ME fluence maps that require subsequent conversion into clinically deliverable treatment plans. The findings demonstrate that ME optimization can enhance OAR sparing without compromising target coverage, supporting its promise for future clinical application.
10 May 2026
Read appraisal →World journal of urology
Clinical and procedural factors influencing ureteral stent dwell time and removal methods after endourological procedures: a systematic review.
INTRODUCTION: Ureteral stents are routinely used following endourological procedures to ensure adequate drainage and prevent obstruction. However, stent-related morbidity remains common, and optimal stent dwell time and removal methods are not well defined. This systematic review aimed to evaluate clinical and procedural factors influencing ureteral stent dwell time and the methods used for stent removal after endourological interventions. METHODS: A systematic review was conducted in accordance with PRISMA guidelines and registered on PROSPERO. MEDLINE and Embase were searched from inception to October 2025. Randomized controlled trials and comparative observational studies evaluating ureteral stent dwell time and/or removal methods in adults undergoing endourological procedures were included. Risk of bias was assessed using RoB 2 and ROBINS-I tools. RESULTS: Thirty-two studies encompassing 4,373 patients were included. Reported stent dwell times varied widely, most commonly ranging between 10 and 14 days in uncomplicated cases, with longer durations associated with increased rates of encrustation and removal difficulty. Removal techniques included rigid cystoscopy (48.7%), flexible cystoscopy (19.9%), extraction strings (23.5%), and device-assisted methods (7.9%). Less invasive approaches, particularly flexible cystoscopy and extraction-string removal, were consistently associated with reduced pain scores and improved patient comfort, although extraction strings carried a small risk of premature dislodgement. CONCLUSIONS: While practice patterns vary, the evidence suggests that a 10-14 day dwell time might be the optimal window to balance healing with the prevention of encrustation. Less invasive removal approaches, particularly flexible cystoscopy and extraction-string techniques, were generally associated with lower pain scores and high procedural success rates in selected patients. While these methods are safe and better tolerated, extraction strings carried a small, reproducible risk of premature dislodgement. High-quality prospective studies are needed to define determinant-based, individualized stent management strategies.
10 May 2026
Read appraisal →Journal of clinical ultrasound : JCU
Integrative Machine Learning Model Leveraging DCE-MRI and PSA Values for Advanced Risk Stratification in Prostate Cancer
PURPOSE: Accurate grading of prostate cancer is critical for treatment strategies and risk stratification. This study aims to develop a machine learning (ML) model integrating Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) pharmacokinetic parameters with Prostate-Specific Antigen (PSA) values to predict ISUP grade metastatic risk groups. METHODS: This retrospective study included 102 patients with histologically confirmed prostate cancer. DCE-MRI pharmacokinetic parameters (Ktrans, Kep, Ve, CER, MaxSlope, IAUGC) were standardized. The dataset was balanced using the Synthetic Minority Oversampling Technique and split into training, validation, and test sets. ML models, including Random Forest, were evaluated using Area Under the Curve (AUC) values. RESULTS: The Random Forest classifier achieved the highest performance, with an AUC of 0.92. Precision-recall analysis identified an optimal threshold of 0.3, balancing sensitivity and specificity for high-risk group detection. SHAP analysis highlighted PSA, MaxSlope, and Kep as key predictors contributing to model accuracy. CONCLUSION: Integrating DCE-MRI parameters with PSA values using ML algorithms enhances the prediction of ISUP grade metastatic risk groups. This method provides a robust tool for metastasis screening and personalized treatment in prostate cancer.
9 May 2026
Read appraisal →Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes
Training With Local Data Remains Important for Deep Learning MRI Prostate Cancer Detection
OBJECTIVES: Domain shift has been shown to have a major detrimental effect on AI model performance however prior studies on domain shift for MRI prostate cancer segmentation have been limited to small, or heterogenous cohorts. Our objective was to assess whether prostate cancer segmentation models trained on local MRI data continue to outperform those trained on external data with cohorts exceeding 1000. METHODS: We simulated a multi-institutional consortium using the public PICAI dataset (PICAI-TRAIN: 1241 exams, PICAI-TEST: 259) and a local dataset (LOCAL-TRAIN: 1400 exams, LOCAL-TEST: 308). IRB approval was obtained and consent waived. We compared nnUNet-v2 models trained on the combined data (CENTRAL-TRAIN) and separately on PICAI-TRAIN and LOCAL-TRAIN. Accuracy was evaluated using the open source PICAI Score on LOCAL-TEST. Significance was tested using bootstrapping. RESULTS: Just 22% (309/1400) of LOCAL-TRAIN exams would be sufficient to match the performance of a model trained on PICAI-TRAIN. The CENTRAL-TRAIN performance was similar to LOCAL-TRAIN performance, with PICAI Scores [95% CI] of 65 [58-71] and 66 [60-72], respectively. Both of these models exceeded the model trained on PICAI-TRAIN alone which had a score of 58 [51-64] (P < .002). Reducing training set size did not alter these relative trends. CONCLUSION: Domain shift limits MRI prostate cancer segmentation performance even when training with over 1000 exams from 3 external institutions. Use of local data is paramount at these scales.
9 May 2026
Read appraisal →Nuclear medicine communications
Refining deep learning segmentation in gallium-68-prostate-specific membrane antigen-11 positron emission tomography: evaluation of small lesion filtering and intersection-over-union thresholds
PURPOSE: Evaluate how small lesion filtering and different intersection-over-union (IoU) thresholds influence deep learning segmentation of Ga-68-PSMA-11 PET images in prostate cancer. METHODS: A 3D U-Net was trained on 115 patient scans with manual contours as ground truth. Performance was assessed at voxel, lesion and patient levels. Lesions less than 8 voxels (195 mm 3 ) or less than 27 voxels (658 mm 3 ) were optionally discarded, and lesion-level metrics were computed across 10-50% IoU thresholds. RESULTS: Excluding lesions less than 27 voxels increased voxel-level Dice from 0.7975 to 0.8173 and improved precision. Lesion-level metrics were stable across IoU thresholds of 20-40% after 27-voxel filtering, while sensitivity declined at higher overlap thresholds. Patient-level sensitivity and positive predictive value reached 96.6 and 94.5%, respectively. CONCLUSION: Implementing small lesion filtering criteria improves the reliability of automated segmentation outputs, particularly for quantitative evaluation. For lesion-level metrics, defining true positives within the range of 20-40% IoU thresholds is optimal. Further validation through multicenter studies and larger datasets is essential to ensure the generalizability of these findings.
9 May 2026
Read appraisal →Cytopathology : official journal of the British Society for Clinical Cytology
Comparative Evaluation of Transfer Learning Models for Detecting Malignant Cells in Urinary Cytology
AIMS AND OBJECTIVES: In the present paper, we compared the efficiency of six transfer learning models to detect malignant cells in urine cytology. We also applied an ensemble learning with weighted soft voting to assess its importance in the diagnostic accuracy in urine cytology. MATERIALS AND METHODS: The voided urine samples of total 104 cases of urothelial cell carcinoma (UCC) and 86 cases with no malignancy (benign) were selected. All the 104 cases of UCC were histopathology proven high grade urothelial cell carcinoma (UCC). Urine with negative cytology reports were followed up clinically. There were 446 images of benign samples and 1369 images from malignant samples on 100 x objective. We applied six transfer learning models (DenseNet121, inception_v3, ResNet50, MobileNetV2, VGG16 and Xception) to detect malignant cells in urine. To compare the performance of different models, dynamic training optimization was done and each model was auto stopped after their maximum performance. In addition, an ensemble learning with soft voting was used including the top three models to enhance the diagnostic accuracy. RESULT: Xception transfer model showed the highest sensitivity (88.57%), accuracy (86.55%), precision (80.52%) and FI score (84.35%). It was the best performing model. The other two top performing models were InceptionV3 and ResNet50. The area under curve of receiver operating characteristic (AUCROC) was ≤ 90 in all the transfer learning models. The accuracy, sensitivity, specificity, precision, F1-Score and AUCROC of the ensemble transfer learning model were as follows: 92.10%, 95.41%, 85.51%, 91.23%, 93.24% and 0.977 respectively. CONCLUSIONS: First time, we evaluated a large number of transfer learning models in urine cytology to detect malignant cells. All the models showed high sensitivity, specificity and accuracy. In addition, the ensemble learning technique with soft voting showed remarkable superior performance than individual top three transfer learning models. The techniques transfer learning and ensemble models have high potential to use in routine screening of urine.
6 May 2026
Read appraisal →World journal of urology
Thulium fiber laser versus Holmium laser enucleation of the prostate: 24-month outcomes from a prospective randomized non-inferiority trial
PURPOSE: To compare 24-month outcomes of Thulium fiber laser enucleation of the prostate (ThuFLEP) and Holmium laser enucleation of the prostate (HoLEP). METHODS: A 24-month follow-up analysis of a prospective randomized trial including 150 patients (ThuFLEP n = 74, HoLEP n = 76) was conducted. Primary outcome was non-inferior International Prostate Symptom Score (IPSS) and quality of life (QoL) reduction. Secondary outcomes included urinary continence, medication use reduction, erectile and ejaculatory function, and late adverse events. RESULTS: At 24 months, non-inferiority of ThuFLEP regarding IPSS and QoL was confirmed (p = 0.03). Median IPSS improved from 21 preoperatively to 3 after ThuFLEP and from 20 to 4 after HoLEP (p < 0.001), with no significant intergroup differences at any time point (all p > 0.1). Median QoL improved from 4 to 1 in both groups (p < 0.001), likewise without significant differences at any time point (all p > 0.3). Continence rates improved from 74.0% preoperatively to 90.0%, pad usage decreased from 89.8% to 25.4% and ICIQ-SF decreased from 5 to 3 points (all p < 0.001), without intergroup differences (all p > 0.1). Use of medication for lower urinary tract symptoms decreased from 89.4% to 7.7% (p < 0.001). Ejaculatory function declined, while ejaculation-related bother remained unchanged and erectile function improved modestly, all without intergroup differences (all p > 0.1). Three late adverse events occurred exclusively in the ThuFLEP group, without statistical significance (p > 0.1). CONCLUSION: ThuFLEP remains non-inferior to HoLEP for patient-reported functional outcomes at 24 months and demonstrates comparable safety, continence, medication use reduction, and sexual function results over time. Both techniques represent effective, durable and safe surgical options for treating benign prostatic obstruction. TRIAL REGISTRATION NUMBER: DRKS00032699 (18.09.2023, retrospectively registered).
3 May 2026
Read appraisal →ACS applied materials & interfaces
Fingerprint-Inspired Recyclable Electronic Skin for Non-Contact Urinary Incontinence Monitoring and Sensing
The development of high-performance flexible electronics faces a fundamental challenge: balancing sophisticated multimodal sensing and end-of-life environmental sustainability. Drawing inspiration from the human fingerprint, we present a microelectronic-printing-based arch-shaped sensor that resolves this conflict by integrating dual-mode (contact/non-contact) sensing with inherently recyclable components. The device, fabricated through high-resolution printing of liquid metal circuits (with line widths below 200 μm) on functionally tailored substrates, exhibits a sensitivity of 3.07 kPa-1 and a response time under 60 ms. It operates across a broad pressure range (0-15 kPa) in contact mode and senses proximity up to 5 cm. This robust performance enables an integrated wireless system for encrypted communication, gesture-trajectory tracking, and dynamic gesture recognition with 92.67% classification accuracy. Notably, we demonstrate a closed-loop lifecycle for the key functional materials, achieving 86.2% recovery and direct reuse of the liquid metal conductor. This work provides a versatile design strategy that simultaneously meets the demands for performance, functionality, and sustainability, offering a practical platform for future green and intelligent wearable technologies.
3 May 2026
Read appraisal →Journal of investigative surgery : the official journal of the Academy of Surgical Research
Comparison of Functional Outcomes Between Robotic and Laparoscopic Surgery in Rectal Cancer Patients: Systematic Review and Meta-Analysis
BACKGROUND: Robotic and laparoscopic approaches are widely used for rectal cancer surgery. Although robotic systems provide enhanced visualization and dexterity, it remains unclear whether these advantages improve postoperative urinary and sexual function. METHODS: MEDLINE, Embase, Web of Science, and CENTRAL (2000-2025) were searched for studies comparing robotic and laparoscopic rectal cancer surgery. Outcomes included postoperative ileus, urinary retention, and urinary and sexual function. Random-effects meta-analysis was performed using RevMan. Study quality was assessed with MINORS, and certainty of evidence with GRADE. Publication bias was evaluated using funnel plots and Egger's test. RESULTS: Forty-four observational studies (6,121 patients) were included. Robotic surgery was associated with lower urinary retention, though this may reflect publication bias. No significant difference was found in postoperative ileus. Subgroup analyses at 3, 6, and 12 months showed no significant differences in urinary or sexual function. Although pooled results slightly favored robotic surgery, these effects were inconsistent, not sustained, and clinically modest. CONCLUSION: Robotic surgery may reduce urinary retention but shows no consistent functional superiority over laparoscopy. Outcomes at key follow-up points are comparable. As all studies were observational, evidence certainty is low, and findings should be interpreted cautiously. This study provides an updated and comprehensive synthesis of functional outcomes following robotic versus laparoscopic rectal cancer surgery, with a specific focus on clinically relevant time-point analyses (3, 6, and 12 months). Unlike prior meta-analyses, which often emphasize pooled outcomes across heterogeneous follow-up periods, this study demonstrates that no consistent or durable improvements in urinary or sexual function are observed at predefined postoperative intervals. Furthermore, by integrating GRADE-based certainty assessment, this work highlights that the current evidence is predominantly observational and of low to very low certainty. Importantly, the study incorporates contemporary evidence up to 2025, including recent systematic reviews and randomized data, and provides a clinically grounded interpretation by contextualizing effect sizes against minimal clinically important difference (MCID) thresholds. Collectively, this analysis offers a more cautious and clinically meaningful appraisal of functional outcomes, challenging assumptions of functional superiority associated with robotic rectal surgery.
2 May 2026
Read appraisal →Lancet (London, England)
Clinical and bacteriological effectiveness of three different short-course antibiotic regimens and single-dose fosfomycin for uncomplicated lower urinary tract infections in women (SCOUT): a pragmatic, multicentre, open-label, randomised clinical trial
BACKGROUND: Most guidelines recommend nitrofurantoin, fosfomycin, and sometimes pivmecillinam for uncomplicated urinary tract infections (UTIs), but direct comparisons between these antibiotics are needed. This study evaluated the effectiveness and safety of a single dose of fosfomycin compared with two doses of fosfomycin and short-course regimens of nitrofurantoin and pivmecillinam in women with UTI symptoms. METHODS: This phase 4, pragmatic, multicentre, parallel-group, open-label, randomised clinical trial was conducted in Spanish primary care centres from 2022 to 2024. Women aged 18 years or older with at least one UTI-specific symptom (dysuria, urinary urgency, urinary frequency, or suprapubic tenderness) and a positive urine dipstick test for either nitrites or leukocyte esterase were randomly assigned (1:1:1:1) to one of four treatments: a single 3 g dose of fosfomycin, two 3 g doses of fosfomycin, nitrofurantoin (100 mg three times per day for 5 days), or pivmecillinam (400 mg three times per day for 3 days). Doctors and patients were not masked to group assignment. The primary outcome was the proportion of patients with clinical resolution (defined as the disappearance of all infection symptoms) at day 7. This trial is registered with ClinicalTrials.gov (NCT04959331) and EudraCT (2021-001332-26) and is completed. FINDINGS: Of the 804 patients assessed for eligibility between April 4, 2022 and Nov 14, 2024, 768 patients were randomly allocated (191 to the single-dose fosfomycin group, 194 to the two-dose fosfomycin group, 190 to the nitrofurantoin group, and 193 to the pivmecillinam group). Patients had a median age of 48 years (IQR 34-63). Race and ethnicity data were not collected. Among the 720 women with available data included in the primary analysis, single-dose fosfomycin had the lowest proportion of clinical resolution (109 [59%] of 185 patients), while nitrofurantoin had the highest (128 [74%] of 172 patients; difference 15·5 percentage points [95% CI 5·9 to 25·1] vs single-dose fosfomycin; p=0·0168), followed by pivmecillinam (127 [70%] of 182; difference 10·9 percentage points [1·1 to 20·6]; p=0·2352) and the two-dose fosfomycin group (122 [67%] of 181; difference 8·5 percentage points [-1·4 to 18·3]; p=0·6935). Adverse events occurred in 38 (19·9% [95% CI 14·9 to 26·1) of 191 patients who received single-dose fosfomycin, 51 (26·3% [20·6 to 32·9]) of 194 who received two-dose fosfomycin, 51 (26·8% [21·0 to 33·6]) of 190 who received nitrofurantoin, and 41 (21·2% [16·1 to 27·5]) of 193 who received pivmecillinam. Most adverse events were mild and self-limiting, primarily gastrointestinal. Four serious adverse events occurred, of which one was related to the study treatment (one case of pyelonephritis in the pivmecillinam group). INTERPRETATION: Nitrofurantoin was the most effective treatment and single-dose fosfomycin the least effective treatment for UTIs. Adverse events were mild. The role of fosfomycin as a first-line antibiotic for uncomplicated UTI should be re-evaluated. FUNDING: Carlos III Institute of Health, Spanish Ministry of Science and Innovation, and European Regional Development Fund.
2 May 2026
Read appraisal →Journal for immunotherapy of cancer
Phase 2 trial of pTVG-HP ± pTVG-AR DNA vaccines and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)
BACKGROUND: We previously reported a trial using pembrolizumab with a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) in patients with metastatic castration-resistant prostate cancer (mCRPC). Favorable clinical outcomes were associated with T-cell activation, suggesting immune response to vaccination was critical. In the current trial, we evaluated whether immunization with two vaccines, to broaden the T-cell response to other cancer-associated antigens, would elicit greater anti-tumor efficacy. MATERIALS AND METHODS: 60 patients with mCRPC were treated with vaccine on days 1 and 8 of a 3 week cycle, with pembrolizumab given on day 1 of each cycle. Patients in Arm A (n=30) received pTVG-HP as the vaccine, and patients in Arm B (n=30) received pTVG-AR (encoding the ligand-binding domain of the androgen receptor) alternating with pTVG-HP every two cycles. After eight cycles (6 months), patients continued to receive pembrolizumab alone, with the option to receive further booster immunizations at prostate-specific antigen (PSA) progression. The primary objective was 6-month progression-free survival (PFS). Secondary objectives included safety, objective response rate, PSA response rate, overall survival (OS), and immunological evaluations. RESULTS: Overall median time to progression was 24 weeks (24 weeks Arm A, 24 weeks Arm B, p=0.80). The month 6 PFS rate was 51% in Arm A and 45% in Arm B. Median OS was 2.8 years (2.5 years Arm A, 3.7 years Arm B, p=0.16). 20% of patients in each arm experienced a PSA decline of >50%. 20 patients (n=8 Arm A, n=12 Arm B) had measurable disease, and 6/20 (30%) experienced a partial response. Eight patients received booster immunizations after 6 months, 3 of whom subsequently experienced a PSA decline. Three patients in Arm B experienced creatine kinase elevation with or without increased transaminases, which were not observed in Arm A. T cell immune responses to both antigens were detected in patients treated in Arm B. CONCLUSIONS: Treatment with DNA vaccines and pembrolizumab demonstrated anti-tumor activity in terms of PSA declines and objective responses. The addition of pTVG-AR did not significantly increase measures of clinical efficacy; however, it was associated with a slight increase in toxicity to tissues that also express AR. TRIAL REGISTRATION NUMBER: NCT04090528.
27 Apr 2026
Read appraisal →The New England journal of medicine
Transdermal Estradiol Patches in Locally Advanced Prostate Cancer
BACKGROUND: Transdermal estradiol (tE2) is an alternative to luteinizing hormone-releasing hormone (LHRH) agonists as androgen-deprivation therapy in patients with prostate cancer. With tE2, testosterone is suppressed, and the side effects of estrogen depletion due to LHRH agonists and the thromboembolic side effects of oral estrogen are mitigated. METHODS: In this phase 3, noninferiority, randomized trial, we assigned men with locally advanced (M0 and N0 or N+) prostate cancer to receive tE2 patches (100 μg of estradiol every 24 hours) or LHRH agonists. The primary outcome was 3-year metastasis-free survival. The noninferiority margin was 4 percentage points; this corresponded to a target hazard ratio of 1.31, as derived from the observed 3-year metastasis-free survival in the LHRH agonist group. Secondary outcomes included castrate levels of testosterone (<1.7 nmol per liter), overall survival, and safety. RESULTS: Between 2007 and 2022, we recruited 1360 patients at 75 U.K. centers. The median age of the patients was 72 years (interquartile range, 68 to 77); 85% had a T3 tumor stage and 65% an N0 nodal stage. Observed 3-year metastasis-free survival was 87.1% with tE2 and 85.9% with LHRH agonists (hazard ratio for confirmed metastasis or death, 0.96; upper limit of the one-sided 95% confidence interval [CI], 1.11, which met the criterion for noninferiority). Among patients continuing the assigned treatment, castrate levels of testosterone were sustained during the first year after randomization in 85% in each group. Observed 5-year overall survival was 81.1% with tE2 and 79.2% with LHRH agonists (hazard ratio for death, 0.90; 95% CI, 0.75 to 1.07). During treatment, hot flashes occurred in 44% of the patients who received tE2 and 89% of those who received LHRH agonists (grade ≥2 events, 8% and 37%, respectively) and gynecomastia in 85% and 42% (grade ≥2 events, 37% and 9%). CONCLUSIONS: In patients with locally advanced prostate cancer, tE2 was noninferior to LHRH agonists for 3-year metastasis-free survival, with a lower incidence of hot flashes but a higher incidence of gynecomastia. (Funded by Cancer Research U.K. and the U.K. Research Institute Medical Research Council; PATCH ClinicalTrials.gov number, NCT00303784; STAMPEDE-1 ClinicalTrials.gov number, NCT00268476.).
24 Apr 2026
Read appraisal →Human mutation
HSPB6: A Potential Prognostic Biomarker, Inhibiting the Epithelial-Mesenchymal Transition (EMT) Process Through the PI3K/Akt Signaling Pathway Based on the Machine Learning and Experimental Validation
Bladder cancer (BC) is a prevalent malignant tumor worldwide, posing a significant public health burden and challenge to human society. Current therapeutic modalities for BC include surgical treatment, radiotherapy, chemotherapy, targeted therapy, and immunosuppressive therapy. However, almost all patients experience disease progression and ultimately succumb to BC. Our study demonstrated that elevated expression of Heat Shock Protein Beta-6 (HSPB6) correlated with higher clinical grades and stages, establishing it as an independent prognostic risk factor for BC. Enrichment analysis indicated that HSPB6 is associated with the extracellular matrix in BC. Experimental validation revealed that HSPB6 overexpression inhibits the proliferation of BC cell line T24. This effect may be achieved by inhibiting the PI3K/Akt signaling pathway, which in turn leads to inhibition of epithelial-mesenchymal transition (EMT). Furthermore, we developed a prognostic risk model that incorporated DDR2, DPYSL3, MFAP5, PDGFRB, and SPOCD1, allowing accurate prediction of patient outcomes based on immunological status. In conclusion, this study highlights that HSPB6 overexpression can restrain the proliferation of BC cells and inhibit EMT, underscoring its potential as a diagnostic marker and therapeutic target in BC.
23 Apr 2026
Read appraisal →The aging male : the official journal of the International Society for the Study of the Aging Male
The effect of dutasteride on storage symptoms in men with lower urinary tract symptoms: a REDUCE trial analysis
BACKGROUND: Dutasteride is used to treat voiding symptoms; its impact on storage symptoms is unclear. METHODS: We reviewed 8122 men in the placebo and dutasteride arms from the REDUCE trial. Lower urinary tract symptoms outcomes were measured with international prostate symptom score and subscores. RESULTS: At 2-year follow-up, dutasteride significantly reduced the total International Prostate Symptom Score and voiding subscore versus placebo (both p < 0.001), but not storage symptoms (p = 0.09) or nocturia (p = 0.2). By 4 years, improvements in the total score and voiding subscores remained, but now extended to storage symptoms (p < 0.001) and nocturia (p = 0.003), though the impact on storage symptoms was modest (0.62 points improvement). CONCLUSION: While dutasteride reduces storage symptoms, it takes several years, and the overall effect is modest and unlikely to be clinically meaningful. Timely, comprehensive lower urinary tract symptoms management may require additional therapy.
22 Apr 2026
Read appraisal →Spinal cord series and cases
Early transanal irrigation in spinal cord injury-related neurogenic bowel dysfunction: preliminary insights.
STUDY DESIGN: Prospective, randomized, open-label, multicenter, parallel group study. OBJECTIVES: Neurogenic bowel dysfunction (NBD) is a common complication in spinal cord injury (SCI) patients, severely affecting quality of life. While transanal irrigation (TAI) has shown superior efficacy over conservative treatments (CT), its early adoption during the first hospitalization post-injury remains unexplored. This study aimed to compare early TAI initiation versus CT in managing NBD in SCI patients. SETTING: This study involved four spinal units across Italy. METHODS: SCI patients were randomized to receive TAI or CT during a four-week hospital stay, followed by continued treatment at home for 6 months. Bowel function, constipation, and continence were assessed using the Wexner scales, while quality of life was measured using the EQ-5D-5L and Spinal Cord Independence Measure (SCIM) questionnaires. Stool transit time and patient independence were also monitored. RESULTS: Twenty-two patients were enrolled, with the TAI group showing significant improvements in constipation (Wexner score reduction from 13.43 ± 4.24 at baseline to 7.55 ± 2.38 and 8.80 ± 4.16 at 4 weeks and 6 months, p = 0.02) and a trend toward continence improvement. A significant increase in the total SCIM score was observed in the TAI group (p = 0.02), particularly in respiratory and sphincter management. Quality of life improved in both groups, with a notable enhancement in self-care activities for the TAI group (p = 0.006). CONCLUSIONS: These preliminary results suggest early TAI adoption improves bowel management, especially constipation, and enhances patient independence. Larger studies are needed to validate these findings and assess long-term benefits.
22 Apr 2026
Read appraisal →Journal of clinical oncology : official journal of the American Society of Clinical Oncology
CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer
PURPOSE: The CALYPSO study demonstrated activity of savolitinib and durvalumab in MET-driven papillary renal cancer (PRC). We report final efficacy outcomes and exploratory circulating tumor DNA (ctDNA) biomarker analysis. METHODS: This single-arm phase II study evaluated savolitinib and durvalumab in treatment-naïve or pretreated PRC. End points included overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). FoundationOne CDx assessed DNA alterations and MET/PD-L1 or MET/tumor mutational burden (TMB) copositivity. ctDNA collected at baseline and on treatment was correlated with outcomes. RESULTS: At 41-months median follow-up, ORR was 34% (95% CI, 20.0 to 51.0) in the intention-to-treat (ITT) population (N = 41) and 53% (95% CI, 28.0 to 77.0) in MET-driven patients (n = 17). Median PFS was 6.5 (95% CI, 2.7 to 12.0) versus 13.9 months (95% CI, 2.9 to 23.8), and OS was 18.3 (95% CI, 7.3 to 30.7) versus 27.4 months (95% CI, 9.3 to 37.4), in the ITT population and the MET-driven population, respectively. PD-L1 (66% positive) and TMB (median 2.5 mut/Mb) status did not correlate with response. Baseline ctDNA positivity (10/21) correlated with shorter OS (median 7.3 v 33.3 months), while ctDNA clearance and mean variant allele frequency reduction correlated with improved OS (median 31.3 v 7.2 and 31.3 v 15.5 months, respectively). CONCLUSION: Savolitinib plus durvalumab shows OS in MET-driven PRC, supporting the ongoing SAMETA RIII trial (ClinicalTrials.gov identifier: NCT05043090). ctDNA may be a useful predictive biomarker.
21 Apr 2026
Read appraisal →Medicine
Clinical study on the efficacy of electroacupuncture combined with pelvic floor muscle training for female stress urinary incontinence
BACKGROUND: To evaluate the clinical efficacy and synergistic effects of electroacupuncture (EA) combined with pelvic floor muscle training (PFMT) in the treatment of mild-to-moderate stress urinary incontinence (SUI) in women. METHODS: A single-blind (assessor-blinded), 2 × 2 factorial, randomized controlled trial was conducted. A total of 128 SUI patients were allocated to 4 groups: the EA group (sessions every other day, targeting acupoints including Guanyuan [RN4] and Shenshu [BL23]), PFMT group (3 daily sessions), combination group (EA + PFMT), and waitlist group. The intervention lasted for 4 weeks. The primary outcome was the change in 1-hour pad test leakage volume. Secondary outcomes included 72-hour urinary incontinence episodes and International Consultation on Incontinence Questionnaire-Short Form scores. Data were analyzed using intention-to-treat and factorial analysis of variance. RESULTS: The combination group showed the greatest reduction in leakage volume (6.17 g, 95% confidence interval [CI] = 5.89-6.44), significantly outperforming the EA group (4.53 g, 95% CI = 4.26-4.81), PFMT group (2.13 g, 95% CI = 1.85-2.41), and waitlist group (0.38 g, 95% CI = 0.11-0.66; all P < .001). Factorial analysis confirmed significant main effects for EA (mean difference = 5.35 g, 95% CI = 5.15-5.54) and PFMT (mean difference = 4.15 g, 95% CI = 3.95-4.34; both P < .001), but no interaction effect (P = .686). Secondary outcomes showed consistent improvements in incontinence episodes and International Consultation on Incontinence Questionnaire-Short Form scores. CONCLUSION: Combined EA and PFMT significantly alleviated SUI symptoms. Although no synergy was observed, the additive therapeutic effect provided clinical benefits, offering a promising nonsurgical alternative for SUI management.
20 Apr 2026
Read appraisal →JMIR research protocols
Integrating Sperm Microscopy, Environmental Exposures, and Lifestyle Factors for Male Fertility Analysis: Protocol for the Nippon Semen and Environmental Exposure Database (N-SEED) Cross-Sectional Study
BACKGROUND: Conventional semen analysis does not fully capture male reproductive potential. The sperm DNA fragmentation index (DFI) may detect latent infertility, although the sperm chromatin structure assay (SCSA) is costly and technically demanding. Image-based analysis of semen microscopy, including artificial intelligence (AI), may enable lower-cost noninvasive assessment. However, progress is limited by a lack of standardized multimodal datasets linking sperm images with the DFI and relevant covariates. OBJECTIVE: This protocol describes the initial phase of the Nippon Semen and Environmental Exposure Database (N-SEED) initiative. The study aims to (1) establish standardized acquisition and quality control procedures for sperm microscopy/video and DFI measurement; (2) evaluate the feasibility and magnitude of associations between predefined image-/video-derived variables and the DFI; and (3) characterize clinical, environmental, physical, and lifestyle factors that may act as candidate correlates or confounders for subsequent image-based fertility research. METHODS: This multi-institutional cross-sectional study centralized clinical assessment and specimen collection at a single site in Japan. The prespecified group-specific enrollment targets were 25 for group 1 (a relatively homogeneous low-risk cohort for DFI quality control) and 100 for group 2 (apparently healthy community-based adult volunteers for exploratory association analyses). Microscopic sperm videos, automated semen parameters, and sperm oxidative stress data were obtained at collection. SCSA-based DFI assays are currently being performed sequentially. Group 2 participants additionally provided fasting blood and early-morning urine samples for endocrine, metabolic, environmental chemical, and elemental assays. They also underwent physical measurements and completed structured questionnaires/interviews on lifestyle, nutrition, sleep, psychological status, sexual function, and collection conditions. The primary outcome measure is the continuous DFI assessed with SCSA. Group 1 data will be used to evaluate intraday, interday, and interfacility variability and to fix flow cytometry gating settings. In groups 1 and 2, predefined image-/video-derived summary variables after standardized preprocessing will be analyzed against the continuous DFI using correlation analyses and simple linear regression to assess whether sperm microscopy data contain information relevant to sperm DNA integrity. Exploratory categorical DFI analyses will use simple logistic regression. Secondary exploratory analyses will examine candidate covariates and data completeness, including sensitivity analyses. RESULTS: The study was registered in the University Hospital Medical Information Network Clinical Trials Registry on January 18, 2026. Between January 18 and February 21, 2026, 124 unique participants were recruited (group 1: n=25; group 2: n=103; both groups: n=4). Sample and data collection were completed on February 21, 2026. Biospecimen assays and primary association analyses are expected to be completed by March 2028. CONCLUSIONS: This initial N-SEED phase will deliver a standardized, quality-controlled multimodal resource linking sperm microscopy/video data with the DFI and broader physiological and environmental measures. Its immediate contribution is not to provide an immediately deployable clinical AI tool but rather to support feasibility assessment, confounder identification, and planning for subsequent database expansion and external validation of image-based male fertility assessment methods. TRIAL REGISTRATION: UMIN Clinical Trials Registry UMIN000060395; https://tinyurl.com/mryfymw5. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/93803.
19 Apr 2026
Read appraisal →Medicine
Efficacy of floating needles in the treatment of postpartum urinary incontinence and pain: A systematic review and meta-analysis
BACKGROUND: Postpartum pain and urinary incontinence (UI) are the most common postpartum sequelae, which can lead to postpartum anxiety and depression when severe, and seriously affect the quality of life of postpartum mothers. Floating needle (FN) is one of the Chinese medical treatments of the latest in recent years, and studies have shown that FN for postpartum pain and stress urinary incontinence has a positive effect; this study aimed to comprehensively and critically evaluate the available evidence on the effectiveness of FN in managing postpartum pain and UI, and provide the first evidence-based medical evidence for FN intervention for postpartum sequela. METHODS: Computerized retrieval of Chinese databases (CNKI, Wanfang, VIP, and CBM) and English databases (PubMed, Embase, Web of Science, and Cochrane Library) for randomized controlled trials on FN therapy for postpartum pain and UI was conducted up to December 20, 2023. Search terms included "floating needle," "urinary incontinence," and "labor pain." Data extraction and quality assessment were performed on eligible studies. Meta-analysis was conducted using RevMan 5.4, with mean differences (MDs) for continuous outcomes and risk ratios for dichotomous endpoints. RESULTS: A total of 1194 women were included in 8 articles in both Chinese and English, all of which were conducted in China; 6 of the articles were included in the meta-analysis. The FN is more effective in treating postpartum incontinence and pain than the control group (risk ratio = 1.33, 95% confidence interval [CI] = 1.18-1.5, P < .001), and significantly reduced the International Consultation on Incontinence Questionnaire-Short Form score (MD = 1.56, 95% CI = 0.78-2.35, P < .001); FN therapy can significantly reduce the amount of urine leakage in postpartum patients (MD = 1.79, 95% CI = 1.09-2.49, P < .001). CONCLUSION: Our results suggest that FN therapy could be encouraged as one of the routine treatments for postpartum sequelae.
18 Apr 2026
Read appraisal →JMIR formative research
Artificial Intelligence Design for Race-Based Prostate Cancer Stage Classification With Multilayer Perceptron: Feature Selection Optimization Approach
BACKGROUND: Prostate cancer progression exhibits significant variability influenced by biological and racial factors. DNA methylation profiling has shown potential in early cancer detection, but its integration with machine learning across racially diverse populations remains limited. OBJECTIVE: This study aimed to develop a prostate cancer stage classifier for the majority White cohort using DNA methylation data and a multilayer perceptron (MLP) model in order to classify prostate cancer stages into early (stages I-II) and late (stages III-IV) stages and assess its performance when applied to other racial groups to highlight the need for race-specific models. METHODS: Methylation and phenotype data from the TCGA-PRAD (The Cancer Genome Atlas Prostate Adenocarcinoma) dataset were processed using differentially methylated position (DMP) analysis to identify CpG sites correlated with cancer stages. These features were further refined through recursive feature elimination (RFE) and used to train MLP models. Shapley Additive Explanations (SHAP) and Local Interpretable Model-Agnostic Explanations (LIME) were used to interpret the model and identify key DNA methylation features contributing to model predictions. RESULTS: The best-performing model achieved 95% accuracy and up to 99% area under the curve on the majority race (White) training data using 90 selected features. However, performance declined sharply in racial minority groups, revealing the effects of sample imbalance and race-specific methylation patterns. Feature importance examination indicated strong patterns within certain CpG sites driving model predictions. CONCLUSIONS: We propose a race-aware MLP model for prostate cancer stage classification using DNA methylation data, which has been optimized through DMP and RFE-based feature selection. SHAP and LIME confirmed the predictive relevance of selected CpG sites, supporting model transparency. The results highlight high performance within the White cohort but reveal poor generalization to racial minority groups, emphasizing the importance of race-specific modeling strategies.
17 Apr 2026
Read appraisal →Computers in biology and medicine
Empirical evaluation of variability and multi-institutional generalizability of deep learning survival models: application to renal cancer CT scans
Deep learning survival (DLS) modeling has shown significant promise across multiple disease conditions for predicting patient outcomes via biomedical data, but remain relatively under-explored in conjunction with medical imaging. This poses the question of what methodological choices promote model generalization, especially when predicting continuous survival outcomes in external validation cohorts. In this work, we systematically examined the impact of data partitioning, data order, model initialization, and augmentation strategies on the generalization of CT-based DLS survival models in renal cancers. A multi-institutional CT cohort was assembled, leveraging public repositories such as TCGA-KIRC, TCGA-KICH, TCGA-KIRP, and KITS19; totaling 525 patients from across 9 institutions. A 3D ResNet-18 model was trained to predict overall patient survival with a Cox loss function and evaluated across three controlled experiments: (i) random versus covariate-balanced data partitioning, (ii) randomizing vs fixing data ordering and initial model weights, and (iii) varying intensity, spatial, and noise based augmentations; evaluated in terms of concordance index (c-index) and hazard ratio (HR). Intelligent covariate-balanced data partitioning demonstrated optimal performance on an external validation set (c-index 0.74, HR 5.08) compared to random partitioning (c-index 0.56, HR 0.29). Different model initializations significantly impacted the average performance and variance across replicate trainings, while data ordering had little to no effect. Combining multiple augmentations produced the best performance on external validation (c-index +4.76%, HR +44.39%) compared to no augmentations, while most impactful individual augmentation type was additive gaussian noise (c-index +3.17%, HR +23.47%). Our results demonstrate that careful selection of strategies for data partitioning and ordering, weight initialization, and image augmentation are critical for developing robust and generalizable DL models for continuous survival prediction using medical imaging data.
17 Apr 2026
Read appraisal →Pediatric surgery international
Anorectal malformation in adulthood: a systematic review of biological, psychological, and sociological outcomes and experiences
PURPOSE: Anorectal malformations are congenital anomalies involving the rectum, anus, genital, and urinary tracts, and occur in approximately one in 5000 live births. A lack of transition from pediatric to adult health services means little is known about how this condition is experienced in adulthood. The purpose of this review was to discover biopsychosocial challenges and supports experienced by adults living with anorectal malformation. MATERIALS AND METHODS: A systematic quantitative literature review was the preferred method to collect and analyze data. Articles included in the review were sorted into purpose-built datasets, with data coded into biopsychosocial themes and patterns. RESULTS: The most frequently reported biological challenge was surgical intervention; the most frequently reported support was positively framed continence management. The most common psychological challenges were psychosexual concerns such as sexual anxiety, and the most common supports were interventions focused on improving self-perception. The most reported sociological challenge was navigating complex health systems, and the most reported support was forming meaningful relationships. CONCLUSION: Biopsychosocial outcomes experienced by adults born with anorectal malformation remain largely unknown. Social work and psychology can provide therapeutic interventions that enhance emotional wellbeing, psychosocial functioning, and patient-led care.
17 Apr 2026
Read appraisal →Clinical cancer research : an official journal of the American Association for Cancer Research
Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
PURPOSE: Many patients with muscle-invasive bladder cancer (MIBC) are ineligible for cisplatin-based therapy. We conducted a phase II trial of neoadjuvant nivolumab ± ipilimumab for cisplatin-ineligible patients. PATIENTS AND METHODS: Patients with MIBC were enrolled in two consecutive cohorts: (i) nivolumab alone and (ii) ipilimumab/nivolumab. A third cohort with alternative dosing was planned. The primary endpoint was eligibility for cystectomy ≤60 days after last treatment. Correlative analyses were performed, with the PURE-01 trial used as an independent dataset. RESULTS: Fifteen patients enrolled onto each cohort. In cohorts 1 and 2, 12 of 15 and eight of 15 were eligible for cystectomy within 60 days, respectively. Due to cohort 2's failure to meet the primary endpoint, cohort 3 was not initiated. With nivolumab alone, four patients achieved <ypT2ypN0 (26%), with two pathologic complete responses (pCR; 13%). With ipilimumab/nivolumab, three achieved <ypT2ypN0 (20%), with one pCR (7%). One patient after nivolumab and two after ipilimumab/nivolumab had durable clinical complete responses (CR) without cystectomy. Twelve-month recurrence-free survival (RFS) was 79% with nivolumab [95% confidence interval (CI), 61-100] and 61% with ipilimumab/nivolumab (95% CI, 39-95). Sequencing analyses suggest that NCOR1 alterations may be associated with improved clinical outcomes. Gene expression profiling indicated a potential association between tumor-infiltrating immune cells and longer RFS (log-rank P = 0.18); this was also observed in PURE-01 (P = 0.022). CONCLUSIONS: Among cisplatin-ineligible patients with MIBC, nivolumab alone was well tolerated. Ipilimumab/nivolumab caused toxicity that delayed cystectomy. Cases of progression before cystectomy indicated insufficient efficacy of pure neoadjuvant immunotherapy for unselected patients. Despite low response rates, some patients experienced sustained clinical CR without cystectomy.
16 Apr 2026
Read appraisal →Biology of reproduction
The relationship between seminal microbiome and male reproductive wellness: a systematic review
The seminal microbiome, which is composed of different types of bacteria in semen and seminal plasma, has a significant impact on male reproductive health by changing the quality of semen and fertility. Previously regarded as sterile, the male reproductive tract contains microbes originating from the gastrointestinal tract, reproductive organs, and external sources such as sexual partners. Dysbiosis alters sperm parameters, triggers inflammation and oxidative stress, and is associated with conditions such as infertility, HPV infection, prostatitis, prostate cancer, and azoospermia. This systematic review adhered to the PRISMA 2020 guidelines (with 2025 extensions for reproducibility) and examined studies from PubMed, Scopus, and Science Direct (2015-2025, with prior context), concentrating on human, in vitro, and rodent models. Firmicutes, Proteobacteria, Actinobacteria, and Bacteroidetes are among the most important phyla. Beneficial genera, such as Lactobacillus, improve sperm motility, concentration, and DNA integrity, whereas dysbiotic taxa, such as Prevotella, Pseudomonas, and Ureaplasma, are associated with declines. Sexual activity facilitates bidirectional microbial transfer, modifying diversity and fostering the dysbiosis. Inflammatory cytokines, reactive oxygen species, and metabolic disruptions are all involved in this process. Changes that are specific to a disease, such as higher levels of Fusobacterium in HPV-positive samples, worsen the situation. This review highlights how the microbiome alters sperm function and causes infertility. Standardized methods and long-term studies are needed to prove causality. Probiotics and other therapeutic interventions show promise in restoring balance and boosting fertility.
16 Apr 2026
Read appraisal →Human fertility (Cambridge, England)
The global evaluation of the effects of antioxidants on seminal outcomes in infertile men: a systematic review and meta-analysis
The aim of the current review is to summarise information from publications on the impact of antioxidants on seminal outcomes in infertile men. A systematic search was performed in the five valid databases (Scopus, PubMed, Medline, Embase, and Web of Science) utilizing two sets of keywords up to September 2025, according to the PRISMA approach. Of the 11749 papers identified, 101 papers were included in this review, for a total of 11889 infertile men. Sperm concentration, normal sperm morphology, progressive sperm motility, and total sperm motility, were considerably higher in experimental groups compared with control groups. Both sperm concentration (106 mL-1) and total motility (%) were higher in experimental groups compared to control groups with an overall pooled standardised mean difference (SMD) of 2.33 (95% CI: 1.73, 2.94) for sperm concentration and SMD of 1.62 (95% CI: 1.20, 2.04) for total motility (%). Subgroup analysis demonstrated that duration of treatments of more than 6 months were more effective than those of less than 3 months. Based on the findings of this review, no definitive recommendation can be made regarding the use of antioxidants as a therapy for male infertility, and further research is necessary.
16 Apr 2026
Read appraisal →International immunopharmacology
Machine learning derived proliferating T cell-related signature: a novel biomarker for prognosis and treatment efficacy in clear cell renal cell carcinoma
BACKGROUND: Clear cell renal cell carcinoma (ccRCC) exhibits profound molecular heterogeneity, and reliable biomarkers for predicting clinical outcomes are urgently needed. Proliferating T cells (Tprolif) are central to immune system activation but their related signatures in predicting prognosis and therapeutic effect of ccRCC patients remains unexplored. METHODS: We developed a Tprolif-related RCC score (TRRS) using an integrative machine learning framework. Transcriptomic data from the CheckMate025 trial formed the discovery cohort. The model was validated across multiple independent cohorts, including IMmotion151, JAVELIN Renal 101, TCGA-KIRC, and West China Hospital (WCH) cohort from our center. Multi-omics analyses, including spatial and single-cell transcriptomics, were employed to investigate the associated biology and identify key mediators. RESULTS: The final TRRS model, built from 7 genes, demonstrated robust performance in stratifying patients for overall survival (OS) and progression-free survival (PFS) in training and all validation sets. TRRS was a powerful predictor of improved outcomes not only for immune checkpoint inhibitor (ICI) monotherapy but also for ICI-based combination therapy and targeted therapies. Biologically, a high TRRS was associated with aggressive tumor hallmarks, a distinct metabolic profile favoring aerobic glycolysis and glutamine metabolism, and an immunosuppressive tumor microenvironment despite high immune cell infiltration based on WCH cohort transcriptome expression profile. Through multi-omics screening, we identified CST3 as a key target, with spatial and single-cell analyses confirming its role in promoting tumor malignancy and enhancing cell-cell communication among microenvironment components. CONCLUSION: The TRRS is a novel, validated biomarker that effectively predicts prognosis and therapeutic responses in advanced ccRCC. It reflects critical biological features of tumor aggressiveness and immune evasion, with CST3 emerging as a potential central mediator and therapeutic target.
15 Apr 2026
Read appraisal →JMIR aging
Web-Based Personalized Machine Learning Recommendations to Enhance Shared Decision-Making in Prostate-Specific Antigen Screening: Randomized Controlled Trial
BACKGROUND: Prostate‑specific antigen (PSA) screening involves complex trade‑offs between early detection and the risks of overdiagnosis. For older adults (aged ≥50 years), shared decision‑making (SDM) is often hindered by limited health literacy, sensory or cognitive impairments, and multimorbidity, which complicate risk comprehension. Traditional decision aids provide foundational knowledge but are often nonpersonalized. Machine learning (ML) may offer individualized recommendations, yet the psychological and behavioral effects of ML‑assisted SDM in geriatric populations remain poorly characterized. OBJECTIVE: This study aimed to develop and evaluate a web‑based, ML‑driven decision aid integrated into an SDM workflow to provide personalized PSA screening recommendations and to assess its effects on decisional conflict (primary outcome), state anxiety, and decision satisfaction among middle‑aged and older men. METHODS: The study followed a 2‑stage design. First, a model establishment group (n=507) was used to train and evaluate 6 ML algorithms based on clinical and values‑clarification data. A random forest model was selected for its superior performance (mean area under the curve 0.933, SD 0.350; 95% CI 0.902-0.963). Second, a randomized controlled trial was conducted with 367 participants (mean age 64.34, SD 10.30 years) randomly assigned 1:1 to the ML suggestion group (MLSG; n=185) or the control group (CG; n=182). Both groups received video‑based education, counseling, and values clarification; only the MLSG received an ML‑generated "second opinion" recommendation. Primary and secondary outcomes were assessed using the Decisional Conflict Scale (DCS), Spielberger State‑Trait Anxiety Inventory (STAI), and Satisfaction with Decision scale. RESULTS: In the randomized controlled trial (n=367), the MLSG reported significantly lower decisional conflict than the CG (total DCS score: mean difference [MD] -3.77, 95% CI -5.55 to -1.99; Cohen d=-0.44; P<.001). The MLSG reported greater perceived support (DCS7: adjusted P=.03), more adequate advice (DCS9: adjusted P<.001), and higher decision confidence (DCS10: adjusted P=.03; DCS11: adjusted P<.001). Regarding psychological well‑being, although total anxiety scores did not differ, the MLSG reported reduced worry (STAI item 6: MD -0.98, 95% CI -1.20 to -0.76; d=-0.89; adjusted P<.001) and increased calmness (STAI item 1: MD 0.30, 95% CI 0.06-0.54; d=0.25; adjusted P=.01). Decision satisfaction was higher in the MLSG across all items (total Satisfaction with Decision score: MD -7.38, 95% CI -8.54 to -6.18; P<.001). Behavioral choices were strongly influenced by the ML recommendation: participants in the MLSG who received an "accept" recommendation were more likely to select "accept" (34/67, 50.7%) than those in the CG (44/182, 24.2%; P<.001). When the system suggested "not now," only 17.8% (21/118) chose "accept," which was lower than in the CG. CONCLUSIONS: Integrating personalized ML recommendations into SDM workflows provides emotional scaffolding for older men, reducing decisional distress and enhancing confidence without undermining autonomy. By addressing geriatric‑specific vulnerabilities through a facilitated digital interface, this ML‑driven approach complements traditional clinical consultations. These findings support the scalable integration of artificial intelligence-assisted decision support to foster patient‑centered care in aging populations.
15 Apr 2026
Read appraisal →Signal transduction and targeted therapy
Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial
Metastatic castration-resistant prostate cancer (mCRPC) after treatment with docetaxel and androgen receptor signaling inhibitors (ARSIs) has limited treatment options. Although enzalutamide has shown activity after abiraterone and docetaxel, robust evidence from randomized phase III trials is lacking. Deutenzalutamide, a novel derivative with slower metabolism and improved pharmacokinetics, may offer enhanced safety and efficacy. This phase III, double-blind trial conducted at 36 centers in China enrolled patients whose disease progressed on or who were intolerant to abiraterone and docetaxel, or who were ineligible for docetaxel. Patients were randomized (2:1) to receive deutenzalutamide 80 mg once daily or placebo until progression or unacceptable toxicity; the primary endpoint was radiographic progression-free survival (rPFS). Of 417 patients (276 deutenzalutamide; 141 placebo), all had previously received abiraterone, and 68% had also received docetaxel. Deutenzalutamide significantly improved rPFS (HR, 0.58; P = 0.0001), reducing the risk of progression by 42%. Although the initial OS analysis was not significant (HR, 0.95), sensitivity analyses adjusting for subsequent therapies showed significant OS benefits (HR, 0.65-0.73). Treatment-related grade 3 or higher adverse events occurred in 22.3% of patients treated with deutenzalutamide, compared with 15.0% with placebo. The most common treatment-related adverse event was anemia, reported at any grade in 21.2% versus 17.9%, with grade 3/4 anemia in 6.6% versus 2.9%, respectively. Notably, no seizures or falls were reported. In summary, deutenzalutamide significantly prolonged rPFS and, after adjustment, showed a potential OS benefit with a favorable safety profile, supporting its promise as a new treatment option for mCRPC. Clinical trial registration: NCT03851640.
13 Apr 2026
Read appraisal →Human mutation
Use of Single-Cell Data and scPagwas Analysis to Identify T Cell Subsets and Construct a Prognostic Model for Clear Cell Renal Cell Carcinoma
BACKGROUND: Clear cell renal cell carcinoma (KIRC), the most prevalent pathological renal cell carcinoma (RCC) subtype, makes up approximately 75%-84% of total cases. KIRC is characterized by high heterogeneity, high metastasis rates, and a poor prognosis. Its incidence rate has continued to rise in recent years. We sought to construct new prognostic models to optimize treatment decisions, improve clinical benefits, and explore potential therapeutic targets. METHODS: This study integrated various omics data including single-cell RNA seq (GSE171306), TCGA-KIRC, GWAS, and validation datasets (GSE29609 and E-MTAB-1980). The scPagwas algorithm combines GWAS with scRNA-seq to identify immune subgroups with high feature correlation. Key genes are identified through the combination of weighted correlation network analysis (WGCNA) with differentially expressed genes (DEGs). We built a clinical prognostic model by using machine learning algorithms and validated it through survival rate and receiver operating characteristic (ROC) analysis. We used cancer drug sensitivity genomics data to analyze drug sensitivity and performed molecular docking to identify potential therapeutic drugs. RESULTS: Using single-cell RNA seq data, we identified T cell subsets as characteristic cell subsets in KIRC through scPagwas analysis. In single-cell analysis, key genes in T cell subsets and genes with PCC values > 0.05 were combined with the core genes in DEGs and WGCNA modules, thus yielding 86 intersecting genes. These genes were significantly enriched in immune-related pathways. We established a clinical prognostic model containing seven risk genes. Low-risk patients exhibited substantial survival advantages. Time-dependent ROC analysis indicated the prognostic model's excellent clinical predictive value. Functional enrichment, immune infiltration, and somatic mutation analyses highlighted different biological mechanisms among risk populations. The SHAP values of the XGBoost and LightGBM machine learning algorithms indicated DOCK8 as a potential biomarker. Drug prediction and molecular docking predicted five potential drugs targeting DOCK8 (finasteride, nocodazole, palonosetron, pifithrin alpha, and topiramate). CONCLUSION: Our systematic analysis of the immune microenvironment, key genes, and prognosis of KIRC highlighted the critical roles of T cell subsets. We additionally established an effective clinical prognostic model. Our findings provide new insights and potential targets for the precise diagnosis and targeted KIRC therapy.
11 Apr 2026
Read appraisal →Journal for immunotherapy of cancer
Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study
BACKGROUND: Simlukafusp alfa (FAP-IL2v) was engineered to preferentially activate CD8+ T and natural killer (NK) cells in tumor microenvironments overexpressing fibroblast activation protein (FAP). Checkpoint inhibitors combined with antiangiogenic agents are standard therapy for metastatic renal cell carcinoma (mRCC), which overexpresses FAP. Here, we explored the efficacy, safety, and pharmacodynamic effects of FAP-IL2v in combination with atezolizumab with or without bevacizumab in patients with mRCC. METHODS: Patients with treatment-naïve or pretreated clear cell and/or sarcomatoid mRCC were eligible. Dose escalation explored FAP-IL2v every 2 weeks (Q2W) with atezolizumab Q2W (doublet, arm A), and with atezolizumab and bevacizumab Q2W (triplet, arm B) in patients treated with up to one prior systemic therapy. Dose extension explored in untreated patients the recommended FAP-IL2v dose administered Q2W (doublet, arm A; and triplet, arm B) or 3-weekly (doublet, arm C; and triplet, arm D). Primary objectives were the recommended FAP-IL2v dose and antitumor activity. Secondary objectives included safety, pharmacodynamics, and exploratory biomarkers in peripheral blood and paired biopsies. RESULTS: By the data cut-off date (31 August, 2021), 66 patients were enrolled. The median duration of treatment was 11.0 months. Objective response rates (ORRs) were 25% for the doublet and 47% for the triplet, and median progression-free survival was 6.3 and 18.3 months, respectively. Safety profiles were consistent with the individual drugs, including expected interleukin-2 (IL-2) class-specific adverse events (AEs). Two deaths were recorded caused by AEs related to study treatment (acute kidney injury, n=1; pancytopenia, n=1). Expansion and activation of NK and T cells, but not regulatory T cells, was observed in peripheral blood, leading to increased tumor infiltration and inflammation in paired biopsies. The addition of bevacizumab led to a reduced angiogenesis signature score and reduced vessel density. CONCLUSION: The combination of FAP-IL2v plus atezolizumab with or without bevacizumab was consistent with the known safety profile of the individual drugs. The maximum tolerated dose was not reached, with a recommended FAP-IL2v dose of 10 mg. ORR was higher among patients receiving the triplet therapy compared with the doublet. Pharmacodynamic results were consistent with the mechanism of action of IL-2, supporting further research in this field.
11 Apr 2026
Read appraisal →PloS one
Randomized trial of transcutaneous tibial nerve stimulation to treat overactive bladder in older women
OBJECTIVES: To evaluate the effects of transcutaneous tibial nerve stimulation (TTNS) associated with behavior therapy (BT) compared to BT alone in the treatment of Overactive Bladder Syndrome (OAB) in older women. STUDY DESIGN: Randomized controlled clinical trial in two groups, G1 that received BT (n = 19) and G2 with the addition of TTNS (n = 19). MAIN OUTCOME MEASURES: The variables analyzed were impact on quality of live (QOL) and degree of discomfort of the symptoms of OAB by International Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ-OAB) and voiding habit by a 3-day voiding diary (VD). The assessments were conducted at the beginning and the end of the treatment. RESULTS: Both groups showed a significant reduction in the impact of QOL by ICIQ-OAB. The G1 (BT) reduced the discomfort of nocturia symptoms and urgency urinary incontinence, while in G2 (BT+TTNS), it just did not present a reduction in the discomfort of urinary frequency by ICIQ-OAB. In the VD, despite G1 presenting an episode reduction of urgency urinary incontinence and nocturia, it showed no significant difference. In the G2, the same variables had significant reduction. CONCLUSION: Behavioral therapy reduced OAB symptoms and discomfort in older women, but its combination with TTNS led to greater improvements, particularly in urgency and nocturia. TTNS was safe, well tolerated, and enhanced quality of life, although further studies with larger samples and longer follow-up are warranted. No adverse events or complications were observed, supporting the safety and tolerability of TTNS in older women with OAB.
7 Apr 2026
Read appraisal →Sexual medicine reviews
Internet-based cognitive behavioral therapy, web-based counseling, and online/digital psychoeducation for male sexual dysfunction: a systematic review
INTRODUCTION: Male sexual dysfunctionhas a substantial impact on psychological well-being and intimate partner relationships. The expanding availability of digital health services has enabled online interventions, such as internet-based cognitive behavioral therapy (ICBT), digital psychoeducation, and web-based counseling, to emerge as alternatives to conventional therapies. OBJECTIVE: To evaluate the effectiveness, feasibility, and acceptability of digital and online interventions for male sexual dysfunction, and to synthesize evidence from randomized, non-randomized, and observational studies on clinical outcomes and patterns of digital engagement. METHODS: This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A comprehensive literature search was conducted across several databases using predefined keywords. Eligible studies included randomized controlled trials, experimental studies, and analytical observational studies published between 2007 and 2024. Extracted data comprised country, participant characteristics, type and duration of intervention, control conditions, outcome measures, and main findings. The primary outcome was improvement in erectile/sexual function using certain parameters, while secondary outcomes included relationship satisfaction, anxiety, and depression. RESULTS: Of 2482 records identified, and 21 met the inclusion criteria. Overall, web-based ICBT and psychoeducational interventions improved erectile function and sexual satisfaction compared with control conditions. Most interventions lasted 6-12 weeks and incorporated therapist feedback or automated systems. Remission rates for erectile dysfunction ranged from 20% to 30%; however, participant adherence was low (<60%). Several studies also reported reductions in performance anxiety and improvements in sexual confidence, with no serious adverse effects. CONCLUSION: Online interventions are promising approaches for managing male sexual dysfunction. Nevertheless, low adherence rates and heterogeneity in intervention formats remain major challenges. The findings also suggest heterogeneous benefits of digital interventions, alongside improved accessibility, reduced stigma, and increased engagement in help-seeking among men with sexual dysfunction. Future research should prioritize strategies to enhance adherence, integrate mobile health technologies, and assess long-term outcomes through large-scale clinical trials.
4 Apr 2026
Read appraisal →Regional anesthesia and pain medicine
Anesthetic approaches and 2-year recurrence rates in non-muscle invasive bladder cancer: a randomized clinical trial
BACKGROUND: The effect of anesthesia methods on non-muscle invasive bladder cancer (NMIBC) recurrence post-resection remains uncertain. We aimed to compare the oncological outcomes of spinal anesthesia (SA) and general anesthesia (GA) in patients with NMIBC. METHODS: This prospective randomized controlled trial recruited 287 patients with clinical NMIBC at Seoul National University Hospital from 2018 to 2020. The patients underwent transurethral resection of the bladder tumor within 4 weeks of randomization. Intrathecal hyperbaric bupivacaine (0.5%) and a mixture of propofol (1-2 mg/kg) and fentanyl (50-100 μg/kg) were used as induction agents in the SA and GA groups, respectively, with desflurane or sevoflurane used for maintaining anesthesia. The primary and secondary outcome measures were disease recurrence and disease progression, respectively, at 2 years after resection. Cumulative incidence of outcomes was compared between the two groups using time-to-event analyses. RESULTS: 15 patients required alternative anesthesia owing to clinical needs such as SA failure or significant obturator reflex, resulting in a modified intention-to-treat (ITT) population of 272 patients. Time-to-event analysis showed a significantly lower recurrence of NMIBC in the SA group than in the GA group, in both ITT (27.4% vs 39.8%) and modified ITT populations (26.8% vs 39.6%). Disease progression occurred more frequently in the GA than in the SA group (15.2% vs 7.8%), although the difference was not statistically significant. CONCLUSIONS: A notable reduction in the 2-year recurrence rate was observed in patients who underwent SA than in those who underwent GA. Thus, SA may be considered the preferred anesthetic approach. TRIAL REGISTRATION NUMBER: NCT03597087.
4 Apr 2026
Read appraisal →The New England journal of medicine
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
BACKGROUND: Patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy proceed directly to radical cystectomy with pelvic lymph-node dissection. Perioperative therapy may improve outcomes in this population. METHODS: In this phase 3, open-label trial, participants with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based chemotherapy were randomly assigned to perioperative (neoadjuvant and adjuvant) enfortumab vedotin, an antibody-drug conjugate directed at nectin-4, plus pembrolizumab and surgery (9 total cycles of enfortumab vedotin [1.25 mg per kilogram of body weight on days 1 and 8] plus 17 total cycles of pembrolizumab [200 mg on day 1 every 3 weeks], with surgery after 3 cycles) or surgery alone (control). The primary end point was event-free survival. Key secondary end points were overall survival and pathological complete response (absence of viable tumor after surgical resection). Other secondary end points included safety. RESULTS: A total of 344 participants underwent randomization (170 in the enfortumab vedotin-pembrolizumab group and 174 in the control group). At data cutoff, median follow-up was 25.6 months (range, 11.8 to 53.7). Surgery was performed in 87.6% of participants in the enfortumab vedotin-pembrolizumab group and in 89.7% in the control group. At 2 years, estimated event-free survival was 74.7% in the enfortumab vedotin-pembrolizumab group and 39.4% in the control group (hazard ratio for an event or death, 0.40; 95% confidence interval [CI], 0.28 to 0.57; two-sided P<0.001); estimated overall survival was 79.7% and 63.1% (hazard ratio for death, 0.50; 95% CI, 0.33 to 0.74; two-sided P<0.001). A pathological complete response had occurred in 57.1% and 8.6% of the participants (estimated difference, 48.3 percentage points; 95% CI, 39.5 to 56.5; two-sided P<0.001). Adverse events occurred in all participants in the enfortumab vedotin-pembrolizumab group (grade ≥3, 71.3%; grade ≥3 drug-related, 45.5%) and in 64.8% in the control group (grade ≥3, 45.9%). CONCLUSIONS: Perioperative enfortumab vedotin plus pembrolizumab and surgery led to significantly better event-free and overall survival outcomes and a greater percentage of participants with pathological complete response than surgery alone in a predominantly cisplatin-ineligible population with muscle-invasive bladder cancer. Safety was also assessed. (Funded by Merck Sharp and Dohme, a subsidiary of Merck [Rahway, NJ]; KEYNOTE-905 ClinicalTrials.gov number, NCT03924895.).
4 Apr 2026
Read appraisal →Clinical chemistry
Discovery of an Artificial Intelligence Label Feedback Loop: How the Success of a Clinically Implemented Artificial Intelligence Algorithm Has Created an Unforeseen Challenge to Algorithm Retraining
BACKGROUND: Artificial intelligence (AI) augmented laboratory tests can improve quality, efficiency, cost-effectiveness, and staff satisfaction. However, the clinical success of these tests can introduce unforeseen challenges for model retraining. This study describes the discovery of an "AI label feedback loop" in a clinically implemented AI-augmented kidney stone composition test. METHODS: An AI-augmented kidney stone composition test (V1) has been previously deployed for clinical kidney stone characterization. After several years of clinical use, a retrained model (V2) was developed using 6 times more data. Model performance of both V1 and V2 were evaluated across 3 datasets: a recent production validation (hold-out) set (mostly AI-influenced labels), the original V1 validation set (pre-AI, entirely human-labeled), and a subset of recent cases with exclusively human-generated or human-corrected labels. RESULTS: V2 demonstrated a 10% lower concordance rate than V1 when evaluated on the recent production hold-out set, despite a much larger training dataset. Performance between V1 and V2 was similar when applied to the pre-AI validation set. Notably, V2 outperformed V1 on the recent subset of cases with human-only or human-corrected labels, particularly for less-common stone types. These findings revealed an AI label feedback loop, confounding retraining and evaluation. CONCLUSIONS: The integration of AI into clinical practice can potentially influence reported test results, complicating the development and evaluation of future models. To mitigate AI label feedback loops, ongoing human annotation and careful validation set construction are essential. These strategies can ensure reliable performance assessment and support the safe evolution of clinical AI systems.
4 Apr 2026
Read appraisal →Annals of surgical oncology
A Deep Learning-Based Multimodal Clinico-Histology-Genomic Prognostic Model in Prostate Cancer
BACKGROUND: Prostate cancer remains a leading cause of cancer mortality, yet current risk stratification systems inadequately integrate multidimensional tumor characteristics. This study aims to develop a deep learning-based multimodal prognostic model that combines genomic signatures, histomorphological features from whole-slide imaging (WSI), and clinical parameters to improve risk stratification and therapeutic decision-making. MATERIALS AND METHODS: We constructed a deep learning framework using two independent cohorts: The Cancer Genome Atlas (TCGA) for training and the Prostate, Lung, Colorectal and Ovarian (PLCO) trial for external validation. The model sequentially extracted 768-dimensional histopathological features from hematoxylin and eosin (H&E)-stained WSIs, predicted genomic scores, and histopathological scores, and integrated these with clinical variables via Cox regression to generate a multimodal prognostic score. Performance was evaluated through Kaplan-Meier analysis, Harrell's concordance index, and multivariate Cox regression. RESULTS: The prognostic score demonstrated superior prognostic accuracy (C-index: 0.774) compared with unimodal scores (genomic, histopathological, clinical) and NCCN risk stratification (C-index: 0.706-0.746, p < 0.05). High-risk patients identified by the multimodal model had significantly shorter progression-free intervals (HR = 9.088, 95% CI 6.033-13.691, p < 0.0001) and prostate cancer-specific mortality (HR = 8.787, 95% CI 3.238-23.847, p < 0.0001). Subgroup analysis within NCCN high-risk patients revealed distinct survival trajectories (p < 0.001). Gene set enrichment linked multimodal scores to tumor-relevant pathways. CONCLUSIONS: This integrative model eliminates reliance on genomic testing by computationally inferring genomic features from histopathology, while significantly enhancing prognostic precision. By stratifying heterogeneous patient populations and refining existing NCCN classifications, the prognostic score offers clinical potential for personalized risk assessment and optimized therapeutic strategies.
4 Apr 2026
Read appraisal →Kidney360
Artificial Intelligence in Critical Care Nephrology: Current Applications, Emerging Techniques, and Challenges to Clinical Integration
Artificial intelligence (AI), including machine learning, deep learning, reinforcement learning, and generative AI, has the potential to advance critical care nephrology (CCN) by enhancing prediction accuracy, improving diagnostic capabilities, supporting clinical decision making, and streamlining workflow processes. Current applications in CCN include AKI prediction, nephrotoxin surveillance, intradialytic hypotension forecasting, and AI-guided dialysis and continuous KRT management, with performance often exceeding traditional models. However, the effect on patient-centered outcomes such as mortality, dialysis dependence, and cost-effectiveness remains uncertain. Emerging techniques, such as conformal prediction for calibrated risk estimates, causal inference for intervention modeling, and reinforcement learning for adaptive ultrafiltration, show promise in enhancing reliability, interpretability, and individualized care. Generative AI and large language models extend these applications to clinical documentation, reasoning, and patient education, while raising new challenges, including hallucinations, regulatory oversight, and clinician trust. Persistent barriers such as data heterogeneity, limited external validation, alert fatigue, and economic constraints hinder broad adoption. This review synthesizes the current evidence and outlines four priorities for advancing AI in CCN: ( 1 ) rigorous multicenter validation focused on clinical outcomes, ( 2 ) integration of uncertainty quantification and causal modeling into AI tools, ( 3 ) development of clinician-centered interfaces that minimize cognitive load, and ( 4 ) establishment of transparent, adaptive regulatory and governance frameworks. Realizing the promise of AI in CCN will require multidisciplinary collaboration, fairness and generalizability testing, and sustainable implementation strategies that align technologic innovation with measurable improvements in patient care.
1 Mar 2026
Read appraisal →Gut Microbes
Machine-learning assisted discovery unveils novel interplay between gut microbiota and host metabolic disturbance in diabetic kidney disease
Diabetic kidney disease (DKD) is a serious healthcare dilemma. Nonetheless, the interplay between the functional capacity of gut microbiota and their host remains elusive for DKD. This study aims to elucidate the functional capability of gut microbiota to affect kidney function of DKD patients. A total of 990 subjects were enrolled consisting of a control group (n = 455), a type 2 diabetes mellitus group (DM, n = 204), a DKD group (n = 182) and a chronic kidney disease group (CKD, n = 149). Full-length sequencing of 16S rRNA genes from stool DNA was conducted. Three findings are pinpointed. Firstly, new types of microbiota biomarkers have been created using a machine-learning (ML) method, namely relative abundance of a microbe, presence or absence of a microbe, and the hierarchy ratio between two different taxonomies. Four different panels of features were selected to be analyzed: (i) DM vs. Control, (ii) DKD vs. DM, (iii) DKD vs. CKD, and (iv) CKD vs. Control. These had accuracy rates between 0.72 and 0.78 and areas under curve between 0.79 and 0.86. Secondly, 13 gut microbiota biomarkers, which are strongly correlated with anthropometric, metabolic and/or renal indexes, concomitantly identified by the ML algorithm and the differential abundance method were highly discriminatory. Finally, the predicted functional capability of a DKD-specific biomarker, Gemmiger spp. is enriched in carbohydrate metabolism and branched-chain amino acid (BCAA) biosynthesis. Coincidentally, the circulating levels of various BCAAs (L-valine, L-leucine and L-isoleucine) and their precursor, L-glutamate, are significantly increased in DM and DKD patients, which suggests that, when hyperglycemia is present, there has been alterations in various interconnected pathways associated with glycolysis, pyruvate fermentation and BCAA biosynthesis. Our findings demonstrate that there is a link involving the gut-kidney axis in DKD patients. Furthermore, our findings highlight specific gut bacteria that can acts as useful biomarkers; these could have mechanistic and diagnostic implications.
1 Dec 2025
Read appraisal →Cardiovasc Diabetol
Association of estimated glucose disposition rate with aging acceleration and mortality risk in individuals with cardiovascular-kidney-metabolic syndrome: evidence from two large national population-based studies
OBJECTIVE: This study investigated the relationship between estimated glucose disposal rate (eGDR), aging acceleration (AgeAccel), and mortality in adults diagnosed with cardiovascular-kidney-metabolic (CKM) stages 1 to 4. METHODS: The study utilized data from 4,826 adults with CKM syndrome stages 1 to 4, collected from the National Health and Nutrition Examination Survey (NHANES) conducted during the 2005-2010 survey cycles. The assessment of AgeAccel was performed using two complementary measures: phenotypic AgeAccel (PhenoAgeAccel) and biological AgeAccel (BioAgeAccel). Survey-weighted logistic regression and Cox proportional hazards models were used to assess the associations of eGDR with AgeAccel and mortality risk, respectively. To assess the prognostic value of eGDR for mortality risk, we implemented a suite of nine distinct machine learning models. Additionally, a nomogram was developed to enhance the clinical applicability of our findings. Furthermore, we performed causal mediation analysis to quantify the proportion of the total effect of eGDR on mortality that was mediated through AgeAccel. To ensure the robustness of the results, we replicated our primary analyses using data from the nationally representative China Health and Retirement Longitudinal Study (CHARLS) cohort. RESULTS: Our analysis included 4,826 NHANES participants, among whom we documented 831 all-cause mortality events and 208 cardiovascular disease (CVD)-specific deaths during follow-up. In multivariable-adjusted Cox regression models, each unit increase in eGDR was significantly associated with a 10% reduction in all-cause mortality risk (Hazard ratio [HR] = 0.90, 95% Confidence interval [CI] 0.86-0.93) and a 13% decrease in CVD mortality risk (HR = 0.87, 95% CI 0.81-0.93). Additionally, eGDR showed a negative association with AgeAccel, including both BioAgeAccel (odds ratio [OR] = 0.85, 95% CI 0.82-0.87) and PhenoAgeAccel (OR = 0.78, 95% CI 0.75-0.80). For predicting all-cause mortality from eGDR, the K-Nearest Neighbors (KNN) showed superior discrimination (Area Under the Curve [AUC]: 0.926), exceeding the performance of other machine learning algorithms in a comparative evaluation. Mediation analysis revealed that the protective effect of higher eGDR was partially explained by slower PhenoAgeAccel, with mediation effects accounting for 23.53% and 15.73% of the total impact on all-cause and CVD mortality, respectively. CONCLUSIONS: In the CKM population, lower eGDR levels may be associated with both AgeAccel and an increased risk of mortality, with AgeAccel potentially mediating the relationship between eGDR and mortality. These findings suggested that eGDR could serve as a potential predictor and intervention target for delaying aging and reducing mortality risk.
1 Oct 2025
Read appraisal →